var title_f9_11_9392="Mucinous carcinoma lung gross";
var content_f9_11_9392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucinous carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A resected mucinous carcinoma of the lung appears as a well circumscribed mass with a gelatinous texture. The appearance is indistinguishable from that seen in typical non-pulmonary mucinous carcinomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9392=[""].join("\n");
var outline_f9_11_9392=null;
var title_f9_11_9393="Deflazacort: International drug information";
var content_f9_11_9393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Deflazacort: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4323397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azacortid (AR);",
"     </li>",
"     <li>",
"      Calcort (BR, CH, DE, GB, LU, MX);",
"     </li>",
"     <li>",
"      Deflan (IT);",
"     </li>",
"     <li>",
"      Dezacor (ES);",
"     </li>",
"     <li>",
"      Flamirex (AR);",
"     </li>",
"     <li>",
"      Flantadin (IT);",
"     </li>",
"     <li>",
"      Lantadin (AT);",
"     </li>",
"     <li>",
"      Rosilan (PT);",
"     </li>",
"     <li>",
"      Zamene (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory for use in conditions responsive to corticosteroid therapy",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 120 mg; maintenance: 3-18 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Drops: 22.75 mg/mL [One drop = 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 6 mg, 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10361 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9393=[""].join("\n");
var outline_f9_11_9393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4323397\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978419\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978422\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978418\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821081\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978421\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9394="Corona phlebectasia";
var content_f9_11_9394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F86549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F86549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Corona phlebectasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Corona phlebectasia is&nbsp;a 'crown' of telangiectasias and/or reticular veins around the ankle",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9394=[""].join("\n");
var outline_f9_11_9394=null;
var title_f9_11_9395="Hexaminolevulinate: Drug information";
var content_f9_11_9395=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hexaminolevulinate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/16/22787?source=see_link\">",
"    see \"Hexaminolevulinate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10503149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cysview&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10524688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contrast Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10524714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cystoscopic examination:",
"     </b>",
"     Intravesical instillation: 50 mL (100 mg) instilled into empty bladder via urinary catheter",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11239525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, intravesical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cysview&trade;: 100 mg [supplied with diluent and adapter]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10524715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravesical instillation: Slowly instill solution via intravesical catheter into empty bladder; catheter may be a straight or intermittent urethral catheter with a proximal funnel opening to accommodate a Luer Lock adapter. Catheters may be vinyl (uncoated or coated in hydrogel), latex (amber or red), or silicone; do not use catheters coated or embedded with silver or antibiotics.  Indwelling catheters (eg, Foley catheters) may only be used if inserted shortly before and removed following instillation of hexaminolevulinate. Following instillation, instruct the patient to retain the solution for at least 1 hour (maximum: 3 hours); solution should be evacuated immediately prior to the initiation of the cystoscopic procedure (&le;30 minutes).  If the patient retained the solution for &lt;1 hour, allow 1 hour to pass from the instillation to the initiation of cystoscopic examination. After voiding of the bladder, the perineal skin region should be washed with soap and water and dried.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10524689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Detection of non-muscle invasive papillary cancer of the bladder; used in conjunction with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10524693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hexaminolevulinate, derivatives of aminolevulinic acid or any component of the formulation; porphyria; gross hematuria; bacillus Calmette-Gu&eacute;rin (BCG) immunotherapy or intravesical chemotherapy within the past 90 days",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10524694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis and anaphylactoid shock, have been reported following administration. Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Failed detection: Cystoscopic examination with hexaminolevulinate should not replace random biopsies or other procedures usually performed in the cystoscopic evaluation for cancer; hexaminolevulinate failed to detect 10% of malignant lesions in clinical trials. Both light settings of the PDD system (white before blue) must be used for the most accurate detection of malignancies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; False fluorescence: Fluorescent areas detected during blue light cystoscopy may not always demonstrate a bladder mucosal lesion, especially if the mucosal area had not previously been classified as malignant during white light cystoscopy. Fluorescent areas may also result from inflammation, cystoscopic trauma, scar tissue, or bladder mucosal biopsy from previous examinations.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11304607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: May diminish the diagnostic effect of Hexaminolevulinate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10524690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10524691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if benefits outweigh the risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10524692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16570880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if hexaminolevulinate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering hexaminolevulinate to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cysview Intravesical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $720.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gliolan (PT);",
"     </li>",
"     <li>",
"      Hexvix (AT, BE, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IE, IT, NL, NO, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10524707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Upon intravesical administration, hexaminolevulinate, an ester of aminolevulinic acid and a porphyrin precursor, enters urinary epithelial cells and is used in the formation of photoactive intermediate protoporphyrin IX (PpIX) and other photoactive porphyrins (PAPs). PpIX and PAPs are thought to preferentially accumulate in neoplastic cells. Following photoexcitation with the Karl Storz D-Light Photodynamic Diagnostic (PDD) system, PpIX and PAPs fluoresce and can be used to detect malignant lesions on cystoscopy; fluorescence from tumor tissue appears bright red and demarcated.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10524709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Intravesical: 7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Biphasic; Terminal: ~76 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jocham D, Witjes F, Wagner S, et al, &ldquo;Improved Detection and Treatment of Bladder Cancer Using Hexaminolevulinate Imaging: A Prospective, Phase III, Multicenter Study,&rdquo;",
"      <i>",
"       J Urology",
"      </i>",
"      , 2005, 174(3):862-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9395/abstract-text/16093971/pubmed\" id=\"16093971\" target=\"_blank\">",
"        16093971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16072 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9395=[""].join("\n");
var outline_f9_11_9395=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503149\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524688\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524714\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897499\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897500\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239525\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524689\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524693\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524694\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299445\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11304607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524690\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524691\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524692\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570880\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322863\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992819\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524707\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524709\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/16/22787?source=related_link\">",
"      Hexaminolevulinate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9396="Flea bites thigh";
var content_f9_11_9396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Flea bites thigh",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insect bites. These flea bites are grouped in a characteristic nonfollicular pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9396=[""].join("\n");
var outline_f9_11_9396=null;
var title_f9_11_9397="Recluse spider A";
var content_f9_11_9397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Female recluse spider A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spider appears larger than actual size. Mature recluse spiders have a body length (not including legs) of 7 to 10 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard S Vetter, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9397=[""].join("\n");
var outline_f9_11_9397=null;
var title_f9_11_9398="Triptorelin: Drug information";
var content_f9_11_9398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triptorelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/12/44227?source=see_link\">",
"    see \"Triptorelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trelstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Decapeptyl&reg;;",
"     </li>",
"     <li>",
"      Trelstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Advanced prostate carcinoma:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75 mg once every 4 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg once every 12 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg once every 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) (adjunctive therapy):",
"     </b>",
"     <i>",
"      Canadian labeling (Decapeptyl&reg;; not available in U.S.):",
"     </i>",
"     Females: SubQ: Usual dose: 0.1 mg once daily initiated on day 2 or 3 or days 21-23 of cycle (or 5-7 days prior to expected onset of menses). Dose may be adjusted according to ovarian response as measured by ovarian ultrasound with or without serum estradiol levels. Treatment is continued until follicles achieve suitable size (typically 4-7 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of paraphilia/hypersexuality (unlabeled use; Guay, 2009; Thibaut, 1993):",
"     </b>",
"     Males:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     May cause an initial increase in androgen concentrations which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1-2 months (Guay, 2009). Avoid use in patients with osteoporosis or active pituitary pathology.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Test dose: 1 mg (observe for hypersensitivity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 3.75 mg monthly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15387828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, compared to healthy subjects, triptorelin exposure was increased in moderate to severe renal impairment; the significance of these findings has not been determined.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15387886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, compared to healthy subjects, triptorelin exposure was increased in hepatic impairment (degree not specified); the significance of these findings has not been determined.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trelstar&reg;: 3.75 mg, 11.25 mg, 22.5 mg [contains polylactide-co-glycolide, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15387837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as acetate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decapeptyl&reg;: 100 mcg/mL (equivalent to 95.6 mcg triptorelin free base) (1 mL) [prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F231888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Administer by I.M. injection into the buttock; alternate injection sites. Administer immediately after reconstitution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Decapeptyl&reg; (Canadian availability; not available in U.S.) is administered by subcutaneous injection into the lower abdomen. If a dose is missed, it can be administered on the same day; however, do not double doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of advanced prostate cancer",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Decapeptyl&reg; (Canadian labeling; not available in U.S.): Adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F231946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endometriosis,",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization, precocious puberty, uterine sarcoma; treatment of paraphilia/hypersexuality",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"     As reported with all strengths; frequency of effect may vary by strength:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (59% to 73%), glucose increased, testosterone levels increased (peak: days 2-4; decline to low levels by weeks 3-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased, RBC count decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (2% to &gt;10%),  ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Skeletal pain (12% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Leg edema (6%), hypertension (1% to 4%), chest pain (2%), edema (2%), peripheral edema (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 7%), pain (2% to 3%), dizziness (1% to 3%), fatigue (2%), insomnia (1% to 2%), emotional lability (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (2%), gynecomastia (2%), libido decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), anorexia (2%), constipation (2%), dyspepsia (2%), vomiting (2%), abdominal pain (1%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Erectile dysfunction (10%), testicular atrophy (8%), impotence (2% to 7%), dysuria (5%), urinary retention (&le;1%), urinary tract infection (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg pain (2% to 5%), back pain (1% to 3%), leg cramps (2%), arthralgia (1% to 2%), extremity pain (1%), myalgia (1%), weakness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (1%), eye pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2%), dyspnea (1%), pharyngitis (1%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Reproductive studies:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage (2% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site inflammation (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4% to 5%), fatigue (3% to 4%), malaise (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Spontaneous abortion (7%), dysmenorrhea (2% to 6%), OHSS (3%), hot flashes (2%), ovarian cyst (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 10%), vomiting (3%), abdominal distension (2%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Pelvic pain (6%), adnexa uteri pain (2%), leukorrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (4% to 7%), injection site bruising (3%), injection site reaction (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Postprocedural pain (4%), back pain (3%), postoperative pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (4%), pharyngitis (3%), dyspnea (2%), rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza-like symptoms (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reaction, anaphylaxis, angioedema, bladder outlet obstruction, hematuria, hypersensitivity reactions, circulatory collapse, hematuria, hypersensitivity reactions, injection site necrosis, neuropathy, pituitary apoplexy, renal dysfunction, spinal cord compression; thromboembolic events (cerebrovascular events, DVT, MI, pulmonary emboli, thrombophlebitis, TIA); tumor flare, urethral obstruction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triptorelin or any component of the formulation, other GnRH agonists or GnRH; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Breast-feeding women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone density: Use with caution in patients with risk factors for decreased bone mineral density; may increase risk for osteoporosis and bone fractures particularly with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Hyperglycemia has been reported with androgen deprivation therapy (in prostate cancer) and may manifest as diabetes or worsening of pre-existing diabetes. Monitor blood glucose and/or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Angioedema, anaphylaxis, and anaphylactic shock  have rarely occurred; discontinue use if severe reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome: Decapeptyl&reg; (Canadian availability; not available in U.S.) may increase the risk of ovarian hyperstimulation syndrome (OHSS) and ovarian cysts. OHSS is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If severe hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly with 24 hours to several days and generally occurs during the 7-10 days immediately following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spinal cord compression: Cases of spinal cord compression have been reported with GnRH agonists; observe patients with metastatic vertebral lesions closely during the first few weeks of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Testosterone surge/tumor flare: Transient initial increases in testosterone can lead to worsening symptoms (bone pain, hematuria, urethra/bladder outlet obstruction, neuropathy, spinal cord compression) of prostate cancer during the first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Patients with preexisting depression should be monitored closely during therapy; mood changes including depression have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary tract obstruction: Observe patients with urinary tract obstruction closely in the first few weeks of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F231893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in pregnant women. When used for ART, pregnancy must be ruled out prior to therapy and nonhormonal contraception should be used until menses occurs. Due to the short half-life of triptorelin (formulations used for ART), it is not expected to be present in the maternal serum at the time of embryo transfer. In case reports, spontaneous abortion, congenital anomalies, and other adverse events have been reported following triptorelin (Decapeptyl&reg;) exposure during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F231918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Trelstar Depot Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75 mg (1): $975.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Trelstar Depot Mixject Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.75 mg (1): $975.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Trelstar LA Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg (1): $2927.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Trelstar LA Mixject Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     11.25 mg (1): $2927.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Trelstar Mixject Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22.5 mg (1): $5855.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F231884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum testosterone levels, prostate-specific antigen, glucose and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (periodically)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Decapeptyl&reg; (Canadian availability; not available in U.S.): Negative pregnancy test prior to initiation of therapy; signs/symptoms of allergic reaction for 30 minutes after administration; ultrasound and/or estradiol levels to assess follicle development; ultrasound to assess number and size of follicles",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Treatment of paraphilia/hypersexuality (unlabeled use): The following monitoring has been recommended for other GnRH agonists: CBC (baseline, monthly for 4 months then every 6 months); serum testosterone (baseline, monthly for 4 months then every 6 months); serum LH (baseline and every 6 months), FSH (baseline), serum BUN and creatinine (baseline and every 6 months); bone density (baseline and yearly); ECG (baseline) (Reilly, 2000)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arvekap (GR);",
"     </li>",
"     <li>",
"      Decapeptyl (AE, AR, BE, BG, BH, CL, CN, CO, CY, CZ, DE, EC, EG, ES, FR, GB, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, OM, PL, PT, PY, QA, RU, SA, SY, TR, UY, VE, YE);",
"     </li>",
"     <li>",
"      Decapeptyl CR (AE, BH, CY, EG, IL, IQ, IR, JO, KP, KW, LB, LY, MY, NZ, OM, PH, QA, SA, SG, SY, TH, YE);",
"     </li>",
"     <li>",
"      Decapeptyl Depot (AT, CZ, DE, DK, EE, FI, KP, MY, SE);",
"     </li>",
"     <li>",
"      Decapeptyl LP (FR);",
"     </li>",
"     <li>",
"      Decapeptyl Retard (CH);",
"     </li>",
"     <li>",
"      Decapeptyl SR (PK);",
"     </li>",
"     <li>",
"      Diphereline (AU);",
"     </li>",
"     <li>",
"      Diphereline PR (HK, KP, MY, TW);",
"     </li>",
"     <li>",
"      Gonapeptyl (FR, GB, IE);",
"     </li>",
"     <li>",
"      Gonapeptyl Depot (BR);",
"     </li>",
"     <li>",
"      Neo Decapeptyl (BR);",
"     </li>",
"     <li>",
"      Neo-Decapeptyl CR (PE);",
"     </li>",
"     <li>",
"      Pamorelin (NO);",
"     </li>",
"     <li>",
"      Salvacyl (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F231873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. After chronic and continuous administration, usually 2-4 weeks after initiation, a sustained decrease in LH and FSH secretion occurs. When used for ART, prevents premature LH surge in women undergoing controlled ovarian hyperstimulation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 30-33 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Unknown; unlikely to involve CYP; no known metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.8 &plusmn; 1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe renal impairment: 6.5-7.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment: 7.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (42% as intact peptide); hepatic",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(1):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9398/abstract-text/19243704/pubmed\" id=\"19243704\" target=\"_blank\">",
"        19243704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121:831-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9398/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 2000, 45(6):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9398/abstract-text/10986575/pubmed\" id=\"10986575\" target=\"_blank\">",
"        10986575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, Cordier B, and Kuhn JM, &ldquo;Effect of a Long-Lasting Gonadotrophin Hormone-Releasing Hormone Agonist in Six Cases of Severe Male Paraphilia,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand",
"      </i>",
"      , 1993, 87(6):445-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9398/abstract-text/8356897/pubmed\" id=\"8356897\" target=\"_blank\">",
"        8356897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo;",
"      <i>",
"       World J Biol Psychiatry",
"      </i>",
"      , 2010, 11(4):604-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/11/9398/abstract-text/20459370/pubmed\" id=\"20459370\" target=\"_blank\">",
"        20459370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10018 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9398=[""].join("\n");
var outline_f9_11_9398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231908\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231909\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231950\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231912\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231913\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387828\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387886\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231886\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387837\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231870\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231888\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231946\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231948\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231891\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231874\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300181\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231879\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231882\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231893\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231918\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324043\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231884\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231894\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231873\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231890\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/12/44227?source=related_link\">",
"      Triptorelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9399="Angiokeratoma";
var content_f9_11_9399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar angiokeratoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9399=[""].join("\n");
var outline_f9_11_9399=null;
var title_f9_11_9400="General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults";
var content_f9_11_9400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9400/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/11/9400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of treatment of adults with acute lymphoblastic leukemia (ALL) have steadily improved and currently complete remission (CR) can be induced in 75 to 90 percent of patients. Unfortunately, in contrast to children, relapse rates remain high and long-term survival rates are approximately 25 to 50 percent, depending upon patient age and disease characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential benefits of allogeneic hematopoietic cell transplantation (allo-HCT) accrue from the ability to use myeloablative chemoradiotherapy and the immune-mediated reaction of donor lymphocytes directed against residual ALL cells in the recipient (ie, the graft-versus-leukemia reaction). To be effective, the survival benefit should be sufficient to outweigh both the greater expense and higher risk of early toxicity and death and the late complications such as graft versus host disease (GVHD) and sterility. Allo-HCT is commonly used as part of the post-remission therapy of patients with ALL demonstrating high risk features, such as the presence of the Philadelphia chromosome. Results have been best when the allo-HCT is performed in first or second complete remission.",
"   </p>",
"   <p>",
"    This topic review will discuss general issues in hematopoietic cell transplantation for ALL in adults including: selection of the donor, preparative chemoradiotherapy, and the graft-versus-leukemia effect. Outcomes with this procedure in different subsets of adults with ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"     \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DONOR SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred donor for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for ALL is an HLA-matched sibling or matched unrelated donor (MUD). However, fewer than 25 percent of patients in the transplantable age group have an HLA-matched sibling donor. Allo-HCT using a partially matched family member donor or umbilical cord blood is a reasonable option for patients who do not have an HLA-identical matched donor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Matched unrelated donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been steady improvement in the outcome of patients undergoing matched unrelated donor (MUD)-HCT, due in large part to better matching at the HLA loci using molecular methods instead of serology alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Treatment related mortality (TRM) is still high using this treatment modality, and it increases further with age. Thus, MUD-HCT is generally available only to adults younger than 40 or 50 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of the efficacy of MUD-HCT for adults with ALL is difficult because most of the available data comes from registries and includes a large proportion of children. The range of findings can be illustrated by the following studies:",
"     </li>",
"     <li>",
"      The European Group for Blood and Marrow Transplantation (EBMT) retrospectively compared 191 MUD-HCT recipients with 382 autologous-HCT recipients for acute leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/5\">",
"       5",
"      </a>",
"      ]. Patients were matched for diagnosis, age, stage of disease, and year of transplantation. TRM was higher with MUD-HCT (44 versus 15 percent) but the relapse rate was lower (32 versus 55 percent). The two-year leukemia-free-survival (LFS) for all patients with ALL was similar in both groups (39 and 32 percent).",
"     </li>",
"     <li>",
"      Another series compared the results of 337 patients with ALL who received MUD-HCT (only 36 percent of whom were more than 18 years of age) with 214 patients with ALL who underwent autologous-HCT during the period from 1987 to 1993 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/3\">",
"       3",
"      </a>",
"      ]. The TRM for adults undergoing MUD-HCT in second complete remission (CR2) was 48 percent and was even higher for other stages of disease (57 to 68 percent). The relapse rate was approximately 26 percent at one year. For adults in CR2, MUD-HCT yielded an LFS of 42 percent compared with zero percent after auto-HCT.",
"     </li>",
"     <li>",
"      A review of the experience (1988 to 1990) with MUD-HCT facilitated by the National Marrow Donor Program (NMDP) described 127 adults with poor risk ALL [ie, presence of t(9;22), t(4;11), or t(1;19)], with an age range from 16 to 54 years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/6\">",
"       6",
"      </a>",
"      ]. At two years, the cumulative incidence of TRM was 61 percent, while overall survival was 40, 17, and 5 percent for patients transplanted in CR1, CR2 or CR3, or relapsed or resistant disease, respectively. For patients transplanted in CR1, overall survival was 32 percent at four years, with a cumulative incidence of relapse of 13 percent. Independent predictors of better disease-free survival were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transplantation in first complete remission (CR1)",
"     </li>",
"     <li>",
"      Short interval of time between diagnosis and transplantation",
"     </li>",
"     <li>",
"      HLA matching at the DRB1 locus",
"     </li>",
"     <li>",
"      Cytomegalovirus negative status for both donor and host",
"     </li>",
"     <li>",
"      Presence of the Philadelphia chromosome, t(9;22)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subsequent retrospective review of 169 adult patients with Philadelphia chromosome negative ALL who received unrelated donor transplants in CR1 reported five-year rates of TRM, relapse, and overall survival of 42, 20, and 39 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/7\">",
"       7",
"      </a>",
"      ]. The vast majority of patients had at least one feature of poor risk disease. Factors associated with a worse outcome included WBC more than 100 x",
"      <span class=\"nowrap\">",
"       10(9)/L,",
"      </span>",
"      time to CR1 &gt;8 weeks, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When compared with matched related donor transplants, MUD-HCT appears to result in similar survival rates, but higher rates of nonrelapse mortality. A retrospective analysis of 641 adults who underwent allogeneic HCT in CR1 compared the outcomes of patients who underwent related HCT (48 percent) with those who underwent MUD-HCT in Japan between 1993 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/8\">",
"     8",
"    </a>",
"    ]. When compared with those with a related donor, patients with an unrelated donor had similar survival rates (62 versus 65 percent at four years), lower relapse rates (22 versus 32 percent), higher rates of nonrelapse mortality (27 versus 14 percent), and higher rates of grade II-IV acute GVHD (42 versus 30 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Partially matched family member",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option, which would significantly increase donor availability, is to use T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study evaluated this approach in 101 assessable patients with high-risk acute leukemia (AML and ALL), with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Full engraftment was achieved in 100 patients; acute or chronic GVHD developed in 5 and 7 percent of evaluable patients, respectively.",
"     </li>",
"     <li>",
"      Nonrelapse mortality was 38 percent. Relapse rates for those transplanted in remission or relapse were 14 and 45 percent, respectively.",
"     </li>",
"     <li>",
"      Event-free survival was 46 percent for the 24 patients with ALL receiving HCT while in remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATIVE CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparative regimens are generally divided into three categories: myeloablative, nonmyeloablative, and reduced-intensity regimens. Most studies of allo-HCT in ALL have used myeloablative preparative regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H2#H2\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Preparative regimen intensity defined'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myeloablative preparative regimens use very high, \"supralethal,\" doses of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation in an attempt to improve upon the results of conventional treatment. The use of these doses is based upon the dose-response relationship observed in hematologic malignant diseases in general and in ALL in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this concept may not be valid in the present environment of modern intensive chemotherapy and it is possible that sequential treatment with a large number of different agents, each in moderately high doses for repeated courses and delivered over short periods of time, may be more effective.",
"   </p>",
"   <p>",
"    Relapse of disease is responsible for a large proportion of failures from allo-HCT in ALL, suggesting that current conditioning regimes do not eradicate tumor cells sufficiently. Further intensification is limited by parallel increases in treatment-related mortality (TRM). There is no generally agreed upon best preparative regimen prior to transplant regimen, although total body irradiation (TBI) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is the most widely used. For older patients, reduced intensity conditioning regimens are increasingly used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Total body irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total body irradiation is either fractionated over three to five days or given as a single dose. Fractionated TBI is less toxic to normal cells but large radiation doses are more effective at killing resistant tumor cells. Studies in adults with ALL found that single dose TBI was associated with a significantly higher TRM but also a lower relapse rate than fractionated TBI; there was no difference in the overall leukemia-free survival (LFS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total body irradiation is an important risk factor for the development of cataracts, the incidence of which is higher with single dose than fractionated TBI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In one study of 2149 patients with acute leukemia, from the European Group for Blood and Marrow Transplantation registry, the overall 10-year estimated cataract incidence was 60 percent with single dose TBI, 43 percent with fractionated TBI with six or less fractions, and 7 percent with fractionated TBI with more than six fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chemotherapy in combination with TBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of TBI plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is the most common preparative regimen used prior to allo-HCT for ALL. Agents other than the standard cyclophosphamide have been evaluated in combination with TBI in attempts to further intensify the conditioning regimen. Cytosine arabinoside (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ), for example, has potent antileukemic activity, although the data do not indicate a benefit compared with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H6#H6\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Radiation-containing regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 68 consecutive patients with poor risk ALL treated with single dose TBI and 12 courses of high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      revealed a disease-free survival (DFS) of 18 percent at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/14\">",
"       14",
"      </a>",
"      ]. These results were not different from the outcome of patients treated previously at the same institution with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -containing regimens.",
"     </li>",
"     <li>",
"      In another report of 123 patients with ALL, conditioning regimens with TBI plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      yielded similar outcomes, although TBI plus high-dose cytarabine was associated with a higher TRM [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of fractionated TBI and high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    was explored in patients with advanced acute leukemia, and a relatively low relapse rate was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/18\">",
"     18",
"    </a>",
"    ]. A subsequent study of 34 ALL patients transplanted in CR1, 30 of whom had at least one high-risk factor, demonstrated a 64 percent probability of three-year DFS and a 12 percent probability of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/19\">",
"     19",
"    </a>",
"    ]. Direct comparisons between TBI-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and TBI-etoposide regimens have not yet been published but a trial is in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chemotherapy without TBI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to replace TBI in order to improve the antileukemic effectiveness of the conditioning regimen and to reduce TRM and long-term complications. Several regimens have been evaluated, and the most frequently studied has been the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     (Bu/Cy).",
"    </span>",
"    Leukemia-free survival with this regimen is comparable to that obtained with radiation-containing regimens with greater ease of administration. It is not yet known if the incidence of delayed toxic effects such as sterility, cataracts, and secondary malignancy will be different.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data reported to the International Bone Marrow Transplant Registry (IBMTR) compared 70 patients with ALL conditioned with",
"      <span class=\"nowrap\">",
"       Bu/Cy",
"      </span>",
"      to 286 patients conditioned with Cy-TBI; leukemia-free survival (LFS) and the rate of relapse were similar in the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study evaluated the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      (16",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (120",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      as preparative therapy in 39 adults with ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or cyclosporine plus corticosteroids were given for GVHD prophylaxis. Twelve patients died from complications of treatment, 12 relapsed, and 15 survived free of leukemia. The LFS was 42 percent at three years for patients transplanted in CR or at first relapse but only 14 percent at one year for patients with more advanced disease. The incidence of chronic GVHD was high in this study (63 percent) but was associated with improved LFS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91594198\">",
"    <span class=\"h2\">",
"     Reduced-intensity conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced intensity preparative regimens (RIC) are an intermediate category of regimens that do not fit the definition of myeloablative or nonmyeloablative. Such regimens cause cytopenia, which may be prolonged and result in significant morbidity and mortality, and require hematopoietic stem cell support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H2#H2\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Preparative regimen intensity defined'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of the International Bone Marrow Transplant Registry compared the outcomes of 93 adults with Philadelphia chromosome negative ALL in first or second complete remission who underwent RIC matched sibling or unrelated donor transplantation with 1428 patients receiving full-intensity conditioning in the same setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/23\">",
"     23",
"    </a>",
"    ]. The group that received RIC was older (median age 45 versus 28 years) and more likely to receive a peripheral blood graft (73 versus 43 percent), but otherwise had similar prognostic factors. The two groups demonstrated similar age-adjusted survival rates and transplant-related mortality. There was a trend towards less acute and chronic graft-versus-host disease.",
"   </p>",
"   <p>",
"    A second retrospective study from the European Group for Blood and Marrow Transplantation assessed outcomes in 576 older adults (&ge;45 years) with ALL who underwent RIC (127 patients) or myeloablative (449 patients) allogeneic HCT from matched siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/24\">",
"     24",
"    </a>",
"    ]. After a median follow-up of 16 months, RIC resulted in lower nonrelapse mortality (21 versus 29 percent) and a higher rate of relapse (47 versus 31 percent) at two-years. Estimated overall survival rates at two years were similar (48 versus 45 percent).",
"   </p>",
"   <p>",
"    Prospective studies are needed to further define the role of RIC in patients with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GRAFT-VERSUS-LEUKEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations have provided evidence for the existence of a graft-versus-leukemia (GVL) effect in ALL. Relapse rates are higher after syngeneic or T-cell depleted grafts compared with unmanipulated sibling grafts. As an example, a review from 163 transplant centers compared the results of 103 identical twin and 1030 HLA-identical sibling transplants for leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/25\">",
"     25",
"    </a>",
"    ]. The three-year probability of relapse of leukemia was substantially higher in the identical twin transplants for AML (52 versus 16 percent), and for CML (40 versus 7 percent); the GVL effect was less pronounced and not statistically significant for ALL (36 versus 26 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other observations have supported a GVL effect in ALL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GVHD, both chronic and acute, has been associated with a lower rate of relapse.",
"     </li>",
"     <li>",
"      Regression of relapsed leukemia has occasionally been noted when GVHD flared following the discontinuation of immunosuppression.",
"     </li>",
"     <li>",
"      In one study of 84 patients with CML, 23 with AML and 22 with ALL in relapse after BMT, infusions of donor lymphocytes (DLI) were capable of inducing remission in CML (73 percent) and AML (29 percent). There was no response in the patients with ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/26\">",
"       26",
"      </a>",
"      ]. In other reports, however, occasional patients with relapsed ALL have responded to DLI [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the existence of a beneficial allogeneic GVL effect against ALL cells is likely, but its magnitude is still a matter of controversy. Assuming that GVL does operate in ALL, its effect appears to be less powerful than that observed against myeloid leukemias, such as chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .) The high relapse rate (over 50 percent) among patients transplanted for advanced ALL may be due in part to the minimal effectiveness of this immunologic reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"     \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LONG-TERM SURVIVAL AFTER ALLO-HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Late Effects Working Committee of the International Bone Marrow Transplant Registry (IBMTR) studied 1458 patients with ALL treated with allo-HCT between 1980 and 1993 who were alive and free of disease for at least two years after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/29\">",
"     29",
"    </a>",
"    ]. At a median follow-up of 6.7 years, 167 of these patients had died (11 percent). The causes of death were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relapse of ALL &mdash; 48 percent",
"     </li>",
"     <li>",
"      GVHD &mdash; 23 percent",
"     </li>",
"     <li>",
"      New cancer &mdash; 10 percent",
"     </li>",
"     <li>",
"      Organ failure (liver, cardiac, pulmonary, renal) &mdash; 9 percent",
"     </li>",
"     <li>",
"      Infection without GVHD &mdash; 4 percent",
"     </li>",
"     <li>",
"      Other (hemorrhage, interstitial pneumonia, drug reaction, miscellaneous) &mdash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative risks for late death were 3.6, 2.0, and 1.9 for age at transplantation &gt;40, transplantation while not in remission, and female donor with male recipient, respectively. A Karnofsky performance score of more than 90 percent (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ) was noted in 89 percent of the survivors.",
"   </p>",
"   <p>",
"    The presence of graft-versus-host disease (GVHD) is an important posttransplant prognostic factor. GVHD has been associated with a lower incidence of relapse (a presumed reflection of the graft-versus-leukemia effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/16,30,31\">",
"     16,30,31",
"    </a>",
"    ], but also a shortened patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/32\">",
"     32",
"    </a>",
"    ]. Similarly, the use of GVHD prophylaxis without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or corticosteroids has been associated with an increased rate of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9400/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25351604\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allogeneic hematopoietic cell transplantation (allo-HCT) is commonly used as part of the post-remission therapy of patients with acute lymphoblastic leukemia (ALL) demonstrating high risk features, such as the presence of the Philadelphia chromosome. Results have been best when the allogeneic transplant is performed in first or second complete remission. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link&amp;anchor=H21#H21\">",
"       \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The preferred donor is an HLA-matched sibling or a matched unrelated donor (MUD). Allo-HCT using a partially matched family member donor or umbilical cord blood is a reasonable option for patients who do not have an HLA-identical matched donor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Donor selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preparative regimens of chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy are administered prior to allo-HCT in order to provide adequate immunosuppression to prevent graft rejection and to destroy remaining tumor cells. There is no generally agreed upon best preparative regimen prior to transplantation, although total body irradiation (TBI) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is the most widely used. For older patients, reduced intensity conditioning regimens are increasingly used. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preparative chemoradiotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Chemotherapy in combination with TBI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While there appears to be a beneficial allogeneic graft-versus-leukemia (GVL) effect against ALL, its magnitude is still a matter of controversy. Assuming that GVL does operate in ALL, its effect appears to be less powerful than that observed against myeloid leukemias, such as chronic myeloid leukemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Graft-versus-leukemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of graft-versus-host disease (GVHD) is an important post-transplant prognostic factor. GVHD has been associated with a lower incidence of relapse (a presumed reflection of the graft-versus-leukemia effect), but also a shortened patient survival. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Long-term survival after allo-HCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/1\">",
"      Juliusson G, Karlsson K, Lazarevic VLj, et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. Cancer 2011; 117:4238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/2\">",
"      Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant 2012; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/3\">",
"      Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/4\">",
"      Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87:4455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/5\">",
"      Ringd&eacute;n O, Labopin M, Gluckman E, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. Bone Marrow Transplant 1997; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/6\">",
"      Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/7\">",
"      Marks DI, P&eacute;rez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/8\">",
"      Nishiwaki S, Inamoto Y, Sakamaki H, et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116:4368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/9\">",
"      Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/10\">",
"      Longo DL. Chemotherapy for advanced aggressive lymphoma: more is better ...isn't it? J Clin Oncol 1990; 8:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/11\">",
"      Sutton L, Kuentz M, Cordonnier C, et al. Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities. Bone Marrow Transplant 1993; 12:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/12\">",
"      Robinson N, Sullivan KM. Complications of allogeneic bone marrow transplantation. Curr Opin Hematol 1994; 1:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/13\">",
"      Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 1998; 41:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/14\">",
"      Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/15\">",
"      Herzig RH, Coccia PF, Lazarus HM, et al. Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation. Semin Oncol 1985; 12:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/16\">",
"      Champlin R, Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 1989; 73:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/17\">",
"      Weisdorf DJ, Woods WG, Nesbit ME Jr, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome. Br J Haematol 1994; 86:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/18\">",
"      Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/19\">",
"      Snyder DS, Chao NJ, Amylon MD, et al. Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. Blood 1993; 82:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/20\">",
"      Blume KG, Long GD, Negrin RS, et al. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 Suppl 4:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/21\">",
"      Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/22\">",
"      Copelan EA, Biggs JC, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/23\">",
"      Marks DI, Wang T, P&eacute;rez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/24\">",
"      Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116:4439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/25\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/26\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/27\">",
"      Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/28\">",
"      Tzeng CH, Lin JS, Lee JC, et al. Transfusion of donor peripheral blood buffy coat cells as effective treatment for relapsed acute leukemia after transplantation of allogeneic bone marrow or peripheral blood stem cells from the same donor. Transfusion 1996; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/29\">",
"      Soci&eacute; G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/30\">",
"      Uzunel M, Mattsson J, Jaksch M, et al. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001; 98:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/31\">",
"      Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/32\">",
"      Barrett AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9400/abstract/33\">",
"      Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4528 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.102.30.19-457E293076-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9400=[""].join("\n");
var outline_f9_11_9400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25351604\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DONOR SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Matched unrelated donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Partially matched family member",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATIVE CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Total body irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chemotherapy in combination with TBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chemotherapy without TBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91594198\">",
"      Reduced-intensity conditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GRAFT-VERSUS-LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LONG-TERM SURVIVAL AFTER ALLO-HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25351604\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9401="Anaphylaxis: Confirming the diagnosis and determining the trigger(s)";
var content_f9_11_9401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9401/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9401/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9401/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9401/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9401/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/11/9401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4433809\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have experienced an acute episode of anaphylaxis (or suspected anaphylaxis) require evaluation to confirm the diagnosis and determine the trigger(s) and possible contributing factors, such as other medical conditions (comorbidities) and concurrent medications. Equally important in the ongoing care of patients with a history of anaphylaxis is education of the",
"    <span class=\"nowrap\">",
"     patient/family/caregiver",
"    </span>",
"    about avoidance of triggers and recognition and management of recurrent episodes, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433816\">",
"    <span class=\"h1\">",
"     REFERRAL TO AN ALLERGY/IMMUNOLOGY SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a board-certified allergy specialist is indicated in all cases of certain or suspected anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. A thorough evaluation is required to accomplish the following objectives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirm the diagnosis",
"     </li>",
"     <li>",
"      Confirm that the suspect trigger is indeed the true trigger",
"     </li>",
"     <li>",
"      Assess cofactors that might have contributed to the episode",
"     </li>",
"     <li>",
"      Determine if there were other factors that contributed to the severity of anaphylaxis (comorbidities, concurrent medications), which could be modified to help reduce the patient&rsquo;s risk of a subsequent severe or fatal anaphylactic episode",
"     </li>",
"     <li>",
"      Determine if the patient&rsquo;s anaphylaxis trigger is amenable to immunotherapy or desensitization, in order to reduce the long-term risk of anaphylaxis recurrences",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433823\">",
"    <span class=\"h1\">",
"     CONFIRMING THE DIAGNOSIS OF ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial task in evaluating a patient with a history of a recent episode of anaphylaxis is to ensure that the diagnosis is correct. Anaphylaxis presents with the sudden onset of signs and symptoms, usually in more than one body system, within minutes to a few hours of exposure to a trigger [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. It potentially involves more than 40 signs and symptoms and it is not always easy to recognize [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/6\">",
"     6",
"    </a>",
"    ]. The diagnosis and immediate management of anaphylaxis is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of anaphylaxis is broad, and includes common entities such as acute asthma, acute generalized hives,",
"    <span class=\"nowrap\">",
"     anxiety/panic",
"    </span>",
"    attack,",
"    <span class=\"nowrap\">",
"     syncope/faint,",
"    </span>",
"    and choking",
"    <span class=\"nowrap\">",
"     on/aspiration",
"    </span>",
"    of a foreign body, as well as less common diseases, including flushing syndromes (eg perimenopause) and histamine-release syndromes (eg, scombroid poisoning) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. It also varies with age. For example, the differential diagnosis of anaphylaxis in infancy includes some diseases that are unique to this age group (eg, an infant presenting with sudden onset of vomiting, diarrhea, and hypotension may have either anaphylaxis or food protein-induced enterocolitis). In middle-aged or older adults, other diseases in the differential diagnosis are particularly relevant (eg, myocardial infarction, which can occur independently of anaphylaxis or be a presentation of anaphylaxis). In addition, the differential varies with physiologic states, such as pregnancy in which amniotic fluid embolism is an important consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link\">",
"     \"Approach to flushing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The steps involved in confirming the diagnosis of anaphylaxis, after the acute event, can be depicted in algorithmic form (",
"    <a class=\"graphic graphic_algorithm graphicRef76947 \" href=\"UTD.htm?22/57/23455\">",
"     algorithm 1",
"    </a>",
"    ). Each of these steps is discussed in detail in the sections that follow.",
"   </p>",
"   <p>",
"    The diagnosis of anaphylaxis is confirmed if the information obtained is consistent with the chronology, symptoms, and signs of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, the diagnosis of anaphylaxis is not always easy to make, particularly after the initial episode. In this situation, because anaphylaxis is a potentially fatal medical emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], the patient should be equipped to self-treat a potential recurrence in the community, and if another episode occurs, the clinician should plan to re-evaluate the patient and ascertain if exposures common to both the episodes can be detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433830\">",
"    <span class=\"h2\">",
"     History of exposures and activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is supremely important in making the diagnosis of anaphylaxis, determining the trigger(s), and assessing the patient for contributing factors that might increase the risk of severe or fatal anaphylaxis. As an example, after eating in a seafood restaurant, a patient had an episode of acute self-limited urticaria without other symptoms. The episode was never formally evaluated. On a subsequent occasion, she took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    before going to a party, ingested a small amount of shrimp at the buffet, had a few glasses of wine, and developed anaphylaxis while dancing an hour or so later. In this example, the nonsteroidal antiinflammatory drug (NSAID), alcohol, and exercise are potential amplifying factors that might have contributed to the severity of the anaphylaxis symptoms triggered by shrimp.",
"   </p>",
"   <p>",
"    Each past episode of anaphylaxis should be carefully reviewed, starting with the 24 hour period before the onset of symptoms and paying particular attention to the one to two hours immediately preceding symptom onset. Important information can be obtained from family members, caregivers, friends or other witnesses, emergency medical personnel, and emergency department hospital records.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Exposures",
"      </strong>",
"      - Anything that was ingested, injected or otherwise taken into the body during this period should be noted. Foods are the most common trigger of IgE-mediated anaphylaxis in children, teens, and young adults, while insect stings and medications are more common triggers in middle-age or older adults. The table provides a comprehensive list of potential anaphylaxis triggers, categorized by the pathophysiologic mechanism involved (",
"      <a class=\"graphic graphic_table graphicRef70667 \" href=\"UTD.htm?29/0/29708\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/4,5,7-24\">",
"       4,5,7-24",
"      </a>",
"      ]. The mechanisms of anaphylaxis are reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link\">",
"       \"Pathophysiology of anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"       \"History and physical examination in the patient with possible food allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"       \"Clinical manifestations of food allergy: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"       \"An approach to the patient with drug allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Chronology",
"      </strong>",
"      - The chronology of events (time elapsed between exposure to trigger and sudden onset of first symptom[s]) should be consistent with the diagnosis of anaphylaxis. IgE-mediated anaphylaxis usually develops within minutes to a few hours of exposure to the trigger. However, there are exceptions to this. Uncommon, IgE-mediated reactions to the carbohydrate galactose alpha-1,3-galactose in red meat develop four to six hours after ingestion of meat [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/25\">",
"       25",
"      </a>",
"      ]. Also, some types of non IgE-mediated reactions, for example to NSAIDs, have a slightly delayed onset [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/5,19,20\">",
"       5,19,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"       \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Baseline state of health and activities",
"      </strong>",
"      - Patients should be asked about their general health and their activities in the 24 hours preceding symptom onset [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/11,12,26\">",
"       11,12,26",
"      </a>",
"      ]. Relevant history includes a cold or other viral illness (and any over-the-counter remedies taken as treatment), fever, premenstrual state, excessive emotional stress, and disruption of routine; for example, due to travel or festivities. These factors may render patients more susceptible to anaphylaxis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exacerbate anaphylaxis symptoms.",
"      <br/>",
"      <br/>",
"      Other",
"      <strong>",
"      </strong>",
"      activities, including exercise and any intimate contact with others, should be reviewed [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,4,5,13\">",
"       1,4,5,13",
"      </a>",
"      ]. Exercise can be the only trigger for an anaphylaxis episode, or it may only induce symptoms when preceded by ingestion of food or medications such as NSAIDs that enhance intestinal permeability and allergen absorption. Sometimes specific foods such as shellfish, wheat, or celery combined with exercise will trigger symptoms.",
"      <br/>",
"      <br/>",
"      Uncommonly, allergen exposure can occur through kissing or intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"       \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H23#H23\">",
"       \"Management of food allergy: Avoidance\", section on 'Interpersonal contact'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Environmental conditions",
"      </strong>",
"      &ndash; Exposure to unusual environmental conditions should be reviewed, because anaphylaxis symptoms, particularly in patients with exercise-induced anaphylaxis, can be triggered or exacerbated by factors such as high pollen counts, heat and humidity, or cold [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/5,13\">",
"       5,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"       \"Physical urticarias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"       \"Cold urticaria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1824547\">",
"    <span class=\"h3\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain chronic health conditions impair the ability of a patient or caregiver to recognize early signs and symptoms of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef53777 \" href=\"UTD.htm?10/11/10427\">",
"     table 2",
"    </a>",
"    ) and other chronic health conditions increase the risk of severe or fatal anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef65161 \" href=\"UTD.htm?35/39/36476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/6,27-33\">",
"     6,27-33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Health problems that compromise an individual's ability to avoid triggers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recognize early symptoms (eg, visual or auditory impairment, neurologic disease, psychiatric illness such as depression, autism spectrum disorder, attention deficit hyperactivity disorder, cognitive disorder, or substance abuse) might have diminished awareness of anaphylaxis triggers and symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent asthma, especially if symptoms are not optimally controlled, is an important risk factor for severe or fatal anaphylaxis, particularly in patients with food-induced anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/12,27,28\">",
"       12,27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link&amp;anchor=H8#H8\">",
"       \"Food-induced anaphylaxis\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link&amp;anchor=H22#H22\">",
"       \"Fatal anaphylaxis\", section on 'Asthma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other pulmonary and cardiac diseases, including chronic obstructive pulmonary disease (COPD) and coronary artery disease, increase the risk of severe anaphylactic reactions and fatality [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,2,4,29,30\">",
"       1,2,4,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mastocytosis or clonal mast cell disorders are associated with increased risk of life-threatening or fatal anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. These disorders should be considered particularly in patients with stinging insect venom anaphylaxis and in those who experience hypotension during anaphylaxis. Patients with anaphylaxis associated with mast cell disorders may or may not have identifiable allergen-specific IgE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"       \"Mast cell activation disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some patients, severe or fatal anaphylaxis episodes are potentially associated with defects in enzyme pathways involved in degradation of inflammatory mediators, as reflected in increased baseline serum histamine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/34\">",
"       34",
"      </a>",
"      ], increased baseline serum tryptase levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/35\">",
"       35",
"      </a>",
"      ], low serum angiotensin-converting activity leading to increased bradykinin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/26\">",
"       26",
"      </a>",
"      ], and low serum platelet-activating factor (PAF) acetylhydrolase activity leading to increased PAF levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433837\">",
"    <span class=\"h3\">",
"     Concurrent medications and other substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;All medications and substances ingested or used (prescription, over-the-counter, and recreational) in the 24 hours immediately preceding the anaphylaxis episode should be reviewed. Some medications can interfere with a patient&rsquo;s ability to recognize anaphylaxis triggers and early symptoms and signs (",
"    <a class=\"graphic graphic_table graphicRef53777 \" href=\"UTD.htm?10/11/10427\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,4,26\">",
"     1,4,26",
"    </a>",
"    ]. Other medications may affect the patient's likelihood of developing anaphylaxis or ability to respond with compensatory physiologic changes and to respond to treatment (",
"    <a class=\"graphic graphic_table graphicRef65161 \" href=\"UTD.htm?35/39/36476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some central nervous system-active medications, including sedatives, hypnotics, antidepressants, anxiolytics, and first-generation sedating H1-antihistamines potentially impair cognitive function and patients' ability to recognize and avoid anaphylaxis triggers and symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,26\">",
"       1,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethanol and recreational drugs potentially impair judgment with regard to trigger recognition and avoidance and interfere with recognition of symptoms. In addition, ethanol and opiates can exacerbate anaphylaxis symptoms by causing non-immunologic mast cell activation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,11,26\">",
"       1,11,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta-adrenergic blockers, administered orally or topically (eg, eye drops) may be associated with severe anaphylaxis and also potentially make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects and hypertension and reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous epinephrine [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H29#H29\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Glucagon for patients taking beta-blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alpha-adrenergic blockers potentially decrease the effects of endogenous or exogenous epinephrine at alpha-adrenergic receptors, rendering patients less responsive to the alpha-adrenergic effects of epinephrine.",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme inhibitors potentially interfere with endogenous compensatory mechanisms, resulting in more severe or prolonged symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/39\">",
"       39",
"      </a>",
"      ]. Angiotensin II receptor blockers may be less likely to have this effect; however, this is not optimally documented [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a patient is taking a prescription medication that might have contributed to anaphylaxis or interfered with its treatment, discontinuing use of that medication should be considered. The overall benefits and risks of that drug need to be assessed and discussed not only with the patient, but also with other healthcare professionals involved in",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    care and where appropriate, substitution should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. This is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433844\">",
"    <span class=\"h2\">",
"     Review of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency medical services records and emergency department records should be reviewed, specifically with regard to symptoms and signs of anaphylaxis, as well as all medications that were given and the times at which they were administered. Epinephrine is most effective when injected promptly after symptom onset; therefore, the timing of epinephrine injection(s), the dose in relationship to the patient's weight, and the route and site of injection, are important in the interpretation of the clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H36#H36\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Treatment errors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of the patient's, family's, or caregiver's response to the anaphylactic episode may help to identify behaviors that contributed to the severity of the episode and could be modified to reduce future risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients experiencing food-induced anaphylaxis in a restaurant or other public setting sometimes run to the restroom and separate themselves from those who can assist them, potentially leading to delay in injecting epinephrine, and contacting emergency medical services, and even to fatality.",
"     </li>",
"     <li>",
"      Patients who collapse during anaphylaxis are sometimes propped up in the sitting position by well-meaning family or friends, resulting in the \"empty ventricle syndrome\" and sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"       \"Fatal anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with exercise-induced anaphylaxis sometimes try to run for help at the onset of symptoms, although continued exertion after symptom onset is likely to exacerbate the episode [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"       \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"       \"Exercise-induced anaphylaxis: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433851\">",
"    <span class=\"h2\">",
"     Laboratory test results obtained at the time of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of serum tryptase measurements, plasma histamine levels, and other laboratory tests obtained at the time of the anaphylactic episode should be obtained and reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,35,42,43\">",
"     1,35,42,43",
"    </a>",
"    ]. Tryptase levels are mentioned briefly here as an example and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of anaphylaxis is based on sudden onset and rapid evolution of characteristic symptoms and signs, usually in more than one organ system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tryptase levels are not specific for anaphylaxis and are not available on an emergency basis because the assay takes several hours to perform. The blood sample for serum tryptase measurement is optimally obtained 15 minutes to 3 hours after the onset of anaphylaxis symptoms. The tryptase assay is standardized and the range of normal values is similar in adults and children. Tryptase is stable in frozen serum for at least one year.",
"     </li>",
"     <li>",
"      Serial total tryptase measurements during an anaphylactic episode, and measurement of baseline serum tryptase at least 24 hours after resolution of the clinical signs and symptoms of anaphylaxis, might be helpful; however, these two approaches need to be validated further. If the tryptase level is greater than 11.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in acute serum compared to baseline serum, the diagnosis of anaphylaxis is confirmed. If the level is greater than 11.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in both acute and baseline sera, the diagnosis of mastocytosis or clonal mast cell disorders should be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,44\">",
"       1,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An elevated serum tryptase level often supports the clinical diagnosis of anaphylaxis triggered by insect stings or medications, and in patients with anaphylaxis who are hypotensive or in shock. Serum tryptase levels are seldom elevated in food-induced anaphylaxis or in patients with anaphylaxis who are normotensive. Tryptase levels that are within normal limits cannot be used to rule out the clinical diagnosis of anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"       \"Food-induced anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433858\">",
"    <span class=\"h1\">",
"     TESTING FOR ALLERGEN TRIGGER(S)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every effort should be made to identify a patient's specific trigger(s) for anaphylaxis, as this greatly increases his or her chances of avoiding their trigger and preventing recurrence of anaphylaxis (",
"    <a class=\"graphic graphic_algorithm graphicRef63559 \" href=\"UTD.htm?38/59/39870\">",
"     algorithm 2",
"    </a>",
"    ). In addition, attributing anaphylaxis incorrectly to the \"wrong\" allergen potentially puts the patient at greater risk from exposure to the true culprit allergen.",
"   </p>",
"   <p>",
"    The list of reported triggers for anaphylaxis, including food and food ingredients, insect stings or bites, medications, and so forth, continues to lengthen (",
"    <a class=\"graphic graphic_table graphicRef70667 \" href=\"UTD.htm?29/0/29708\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/4,15,16\">",
"     4,15,16",
"    </a>",
"    ]. The clinical history, gathered as described above, is the best means of identifying a suspect trigger and possible co-triggers. (See",
"    <a class=\"local\" href=\"#H4433830\">",
"     'History of exposures and activities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Attempts should be made to verify the trigger even when the clinical history strongly implicates a single, apparently isolated exposure, such as an insect sting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. In this example, the results of venom specific skin tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgE levels are needed to identify the allergen and also determine if there are other related venoms to which the patient is also sensitized. Such tests are important because a course of subcutaneous injections with the relevant stinging insect venom(s) or extract will dramatically reduce the patient&rsquo;s risk of recurrence of anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433865\">",
"    <span class=\"h2\">",
"     Sensitization to allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with anaphylaxis attributed to an IgE-mediated allergy, sensitization to that allergen can be confirmed through allergen skin tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    measurement of allergen specific IgE levels in serum. However, sensitization does not prove that the patient is clinically reactive to that substance or that it was the trigger for the anaphylactic episode. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin testing with standardized extracts is the traditional method for demonstrating sensitization. Standardized extracts are commercially available for insect venoms and penicillins, but not for foods, most medications, biting insect saliva, or natural rubber latex [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/1,5,17,18\">",
"       1,5,17,18",
"      </a>",
"      ]. In patients with a history of food-induced anaphylaxis, the suspect food itself can be used for skin prick testing.",
"     </li>",
"     <li>",
"      In vitro testing systems (eg, the ImmunoCAP System&reg;, Pharmacia Upjohn Diagnostics, Uppsala, Sweden) provide quantitative results expressed in standardized units. As an example, in children older than two years, ImmunoCAP threshold values have been established for egg, milk, peanut, tree nuts, and fish that correspond to a positive predictive accuracy of 95 percent for a reaction on challenge. In children under age two years, 95 percent predictive values have been established only for egg and milk. In adults, 95 percent predictive values have not been established for any foods [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Specific IgE levels measured using a different assay system are not interchangeable with those measured using ImmunoCap [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"       \"Diagnostic evaluation of food allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"       \"Overview of in vitro allergy tests\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The ImmunoCap and other enzyme-linked immunosorbent assays for quantification of allergen-specific IgE levels in serum have replaced the RAST test (radioallergosorbent test) in most clinical laboratories.",
"      <br/>",
"      <br/>",
"      Patients with a history of a clinical reaction to a specific food, in combination with an elevated specific IgE level to that food",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a positive skin test to that food, do NOT require a food challenge for definitive diagnosis. In such patients, challenges are likely to be failed (positive) and can trigger anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"       \"Diagnostic evaluation of food allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"       \"Overview of in vitro allergy tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If anaphylaxis to medications, biological agents, or vaccines to prevent infectious diseases is suggested by the history, skin tests should be performed with the implicated agent and with the relevant excipients that it contains [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/19-24\">",
"       19-24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H22#H22\">",
"       \"An approach to the patient with drug allergy\", section on 'Objective testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of skin tests and in vitro tests for allergen-specific IgE must always be interpreted in the context of the patient's clinical history for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test result documents sensitization to the allergen, however, it does not necessarily prove that the allergen is the causative trigger for symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/43\">",
"       43",
"      </a>",
"      ]. As an example, more than 50 percent of young people in the general population have one or more positive skin tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased specific IgE levels to one or more foods, yet most of these people are able to ingest the foods to which they are sensitized without developing symptoms. Similarly, more than 25 percent of all adults in the general population have one or more positive skin test responses to insect venoms, yet only a small percentage of these individuals experience anaphylaxis after a sting.",
"     </li>",
"     <li>",
"      In carefully selected patients, eg, those without a convincing history of anaphylaxis, and minimal or no sensitization to the implicated allergen, incremental",
"      <span class=\"nowrap\">",
"       challenge/provocation",
"      </span>",
"      tests, conducted in an appropriately equipped and staffed healthcare facility, are required to exclude or confirm some specific allergen triggers (eg, a food or medication, but NOT an insect sting) as the cause of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/15,16,19,20\">",
"       15,16,19,20",
"      </a>",
"      ]. These procedures are time consuming, costly, and associated with some risk to the patient. They should only be conducted by healthcare professionals with training and experience in the prevention and treatment of anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease: NSAID challenge and desensitization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, an individual can experience anaphylaxis triggered by an allergen suggested by the history, yet have negative skin test responses and absent or undetectable specific IgE levels in serum. The optimal time for testing after an anaphylactic episode has not been definitively established in prospective studies. Therefore, in patients who have negative tests that were performed within days or a few weeks of an anaphylactic episode, the tests should be repeated six weeks after the episode [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. The interpretation of skin testing and in vitro testing for allergic disease is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"       \"Overview of in vitro allergy tests\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433872\">",
"    <span class=\"h2\">",
"     Testing for related allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a specific trigger can be identified, it is sometimes necessary to determine if the patient is sensitive to similar substances. This information is used to help the patient avoid all relevant substances and to identify safe alternatives. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with anaphylaxis in response to yellow jacket venom would generally undergo testing with venoms from several Hymenoptera species, and would be offered immunotherapy that included all the venoms to which they were sensitized.",
"     </li>",
"     <li>",
"      A patient with cystic fibrosis and the need for repeated courses of antibiotics who developed anaphylaxis to one cephalosporin may tolerate other cephalosporins, as well as penicillins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433879\">",
"    <span class=\"h1\">",
"     THE PATIENT WITH AN IDENTIFIABLE TRIGGER",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with anaphylaxis must be taught how to recognize and manage anaphylaxis if and when it recurs, including correct use of epinephrine autoinjectors. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with an identifiable trigger must also be given written instructions about how to avoid that trigger. Some allergens are extremely difficult to avoid, and patients may need to dramatically alter their lifestyle to do so successfully. The educational process, as well as tools and resources to assist patients and clinicians, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link&amp;anchor=H4#H4\">",
"     \"Latex allergy: Management\", section on 'Individual avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For some anaphylaxis triggers, interventions are available to reduce the patient&rsquo;s sensitivity to that substance and prevent recurrence of anaphylaxis. For example, anaphylaxis to stinging insects can be prevented by immunotherapy with the relevant venom(s) or extracts and anaphylaxis to certain medications can be prevented by desensitization according to published protocols. A complete list of the available desensitization therapies is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link&amp;anchor=H7657218#H7657218\">",
"     \"Long-term management of patients with anaphylaxis\", section on 'Interventions to reduce sensitivity to specific allergens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433886\">",
"    <span class=\"h1\">",
"     THE PATIENT WITH NO IDENTIFIABLE TRIGGER",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, no trigger can be identified to explain a patient&rsquo;s anaphylactic episode. In this situation, it is important to reconsider the differential diagnosis of anaphylaxis and to consider the possibility of a hidden or novel trigger. In addition, mast cell disorders, including systemic mastocytosis and monoclonal mast cell activation syndrome should be excluded, especially in patients with repeated episodes of anaphylaxis or anaphylaxis-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. A diagnostic approach to patients with suspected mast cell disorders is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no trigger is identified and mast cell disorders have been excluded, the diagnosis of idiopathic anaphylaxis should be assigned [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/45\">",
"     45",
"    </a>",
"    ] and consideration given to prophylaxis with an oral glucocorticoid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and a second (new)-generation H1-antihistamine such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    for two to three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients with anaphylaxis, whether or not a trigger is identified, must be taught how to recognize and manage anaphylaxis if and when it recurs, including proper use of epinephrine autoinjectors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9401/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"     \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4433893\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have experienced anaphylaxis should be referred to an",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialist to confirm the diagnosis, confirm the trigger(s), and determine relevant patient risk factors for severe or fatal anaphylaxis, eg, comorbidities or concurrent medications that could be modified to reduce the patient&rsquo;s risk of recurrences in the future. In addition, some forms of anaphylaxis are amenable to prevention through immunomodulation. (See",
"      <a class=\"local\" href=\"#H4433816\">",
"       'Referral to an allergy/immunology specialist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation involves retaking a detailed medical history of each episode of symptoms and reviewing relevant medical records and laboratory test results. (See",
"      <a class=\"local\" href=\"#H4433823\">",
"       'Confirming the diagnosis of anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every effort should be made to identify a patient's specific trigger(s) for anaphylaxis, in order to provide appropriate recommendations for trigger avoidance, begin immunotherapy or desensitization, if relevant, and prevent future anaphylaxis episodes. (See",
"      <a class=\"local\" href=\"#H4433858\">",
"       'Testing for allergen trigger(s)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If no trigger is identified, the differential diagnosis of anaphylaxis should be reconsidered and the possibility of a hidden or novel trigger should be explored. All patients with repeated episodes of anaphylaxis and no identifiable triggers, should be assessed for a mast cell disorder. (See",
"      <a class=\"local\" href=\"#H4433886\">",
"       'The patient with no identifiable trigger'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"       \"Idiopathic anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with anaphylaxis require regular education about how to recognize and manage recurrent anaphylaxis and about avoidance of confirmed allergen triggers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link\">",
"       \"Long-term management of patients with anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/1\">",
"      Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/2\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/3\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/4\">",
"      Simons FE, Ardusso LR, Bil&ograve; MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/5\">",
"      Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/6\">",
"      Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/7\">",
"      Alves B, Sheikh A. Age specific aetiology of anaphylaxis. Arch Dis Child 2001; 85:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/8\">",
"      Simons FE. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/9\">",
"      Chaudhuri K, Gonzales J, Jesurun CA, et al. Anaphylactic shock in pregnancy: a case study and review of the literature. Int J Obstet Anesth 2008; 17:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/10\">",
"      Campbell RL, Hagan JB, Li JT, et al. Anaphylaxis in emergency department patients 50 or 65 years or older. Ann Allergy Asthma Immunol 2011; 106:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/11\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/12\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/13\">",
"      Robson-Ansley P, Toit GD. Pathophysiology, diagnosis and management of exercise-induced anaphylaxis. Curr Opin Allergy Clin Immunol 2010; 10:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/14\">",
"      Matsuo H, Kaneko S, Tsujino Y, et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on serum allergen levels after wheat ingestion. J Dermatol Sci 2009; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/15\">",
"      Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/16\">",
"      Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol 2010; 125:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/17\">",
"      Bil&ograve; MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009; 39:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/18\">",
"      Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/19\">",
"      Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010; 125:S126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/20\">",
"      Mirakian R, Ewan PW, Durham SR, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009; 39:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/21\">",
"      Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009; 29:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/22\">",
"      Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/23\">",
"      Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin North Am 2007; 27:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/24\">",
"      Kelso JM, Li JT, Nicklas RA, et al. Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/25\">",
"      Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/26\">",
"      Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/27\">",
"      Gonz&aacute;lez-P&eacute;rez A, Aponte Z, Vidaurre CF, Rodr&iacute;guez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010; 125:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/28\">",
"      Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol 2010; 104:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/29\">",
"      Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/30\">",
"      Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/31\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/32\">",
"      Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/33\">",
"      Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009; 123:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/34\">",
"      Hershko AY, Dranitzki Z, Ulmanski R, et al. Constitutive hyperhistaminaemia: a possible mechanism for recurrent anaphylaxis. Scand J Clin Lab Invest 2001; 61:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/35\">",
"      Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/36\">",
"      Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/37\">",
"      Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2003; 3:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/38\">",
"      TenBrook JA Jr, Wolf MP, Hoffman SN, et al. Should beta-blockers be given to patients with heart disease and peanut-induced anaphylaxis? A decision analysis. J Allergy Clin Immunol 2004; 113:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/39\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/40\">",
"      Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171; author reply 1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/41\">",
"      Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/42\">",
"      Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/43\">",
"      Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/44\">",
"      M&uuml;ller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9401/abstract/45\">",
"      Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 391 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9401=[""].join("\n");
var outline_f9_11_9401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4433893\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433809\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433816\">",
"      REFERRAL TO AN ALLERGY/IMMUNOLOGY SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433823\">",
"      CONFIRMING THE DIAGNOSIS OF ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4433830\">",
"      History of exposures and activities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1824547\">",
"      - Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4433837\">",
"      - Concurrent medications and other substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4433844\">",
"      Review of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4433851\">",
"      Laboratory test results obtained at the time of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433858\">",
"      TESTING FOR ALLERGEN TRIGGER(S)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4433865\">",
"      Sensitization to allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4433872\">",
"      Testing for related allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433879\">",
"      THE PATIENT WITH AN IDENTIFIABLE TRIGGER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433886\">",
"      THE PATIENT WITH NO IDENTIFIABLE TRIGGER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4433893\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/391|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/57/23455\" title=\"algorithm 1\">",
"      Confirmation of the diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/59/39870\" title=\"algorithm 2\">",
"      Confirmation of the triggers of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/0/29708\" title=\"table 1\">",
"      Anaphylaxis triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/11/10427\" title=\"table 2\">",
"      Comorbidities and medications affecting recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/39/36476\" title=\"table 3\">",
"      Comorbidities and medications affecting severity and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7610?source=related_link\">",
"      Anaphylaxis in pregnant and breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18281?source=related_link\">",
"      Aspirin exacerbated respiratory disease: NSAID challenge and desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=related_link\">",
"      Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=related_link\">",
"      Exercise-induced anaphylaxis: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=related_link\">",
"      Long-term management of patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9402="Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis";
var content_f9_11_9402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Patrick Deegan, MD, MRCPI, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/11/9402/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/11/9402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. Glucocerebroside (also called glucosylceramide) and several related compounds that are ordinarily degraded to glucose and lipid components accumulate within the lysosomes of cells.",
"   </p>",
"   <p>",
"    GD is one of the few inherited metabolic disorders that can be treated by replacement of the deficient enzyme (enzyme replacement therapy). Because early treatment can prevent development of irreversible complications, early identification is crucial to improving ultimate outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, genetics, clinical manifestations, and diagnosis of GD are discussed here. The initial assessment, routine monitoring, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H792429\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) is the most common lysosomal storage disease. It occurs in approximately",
"    <span class=\"nowrap\">",
"     1/75,000",
"    </span>",
"    births worldwide, but is more prevalent in individuals of Ashkenazi Jewish descent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. There are approximately 20,000 individuals with GD in the United States, based upon a gene frequency study, two-thirds of whom are Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 90 percent of patients have type 1 Gaucher disease (GD1), which is the nonneuronopathic form. This type is most common in the Ashkenazi Jewish population, in which the carrier frequency is approximately 1 in 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/6\">",
"     6",
"    </a>",
"    ] and the frequency of disease-associated genotypes is calculated at 1 in 850 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/7\">",
"     7",
"    </a>",
"    ]. The incidence of GD1 is much lower in non-Jewish populations, occurring in approximately 1 in 40,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/8\">",
"     8",
"    </a>",
"    ] to 1 in 86,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/9\">",
"     9",
"    </a>",
"    ] live births.",
"   </p>",
"   <p>",
"    Type 2 Gaucher disease (GD2, also called acute neuronopathic GD or infantile cerebral GD), has an estimated incidence of 1 in 150,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/10\">",
"     10",
"    </a>",
"    ]. This subtype is not prevalent, comprising about 1 percent of patients in the Gaucher Registry compared with 5 percent for type 3 disease, as a result of the very short lifespan of patients with type 2 GD.",
"   </p>",
"   <p>",
"    The estimated incidence of type 3 GD is 1 in 200,000, but the prevalence is considerably greater than type 2 disease because of the longer survival of these patients. GD3 is panethnic, but with well-studied clusters in Northern Europe, Egypt and East Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) results from deficiency of a lysosomal enzyme glucocerebrosidase (also known as glucosylceramide or acid beta-glucosidase, GBA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. GBA is a glycoprotein enzyme whose major substrate is glucocerebroside, a component of the cell membrane that is distributed widely in many organs. In the normal lysosome, the protein saposin C is thought to present glucocerebroside to GBA and thereby activate the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In affected patients, the deficiency of GBA leads to accumulation of glucocerebroside and other glycolipids within the lysosomes of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2\">",
"     2",
"    </a>",
"    ]. The tissue levels of these compounds may be increased 20 to 100 times [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/13\">",
"     13",
"    </a>",
"    ]. The deacylated form of glucosylceramide, glucosylsphingosine, is particularly elevated in neuronopathic disease and may have a role in the pathogenesis of neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of GD result from the accumulation of the lipid-laden macrophages in the spleen, liver, bone marrow, bone, and other",
"    <span class=\"nowrap\">",
"     tissues/organs.",
"    </span>",
"    However, pathologic lipid accumulation in macrophages accounts for less than 2 percent of the additional tissue mass in liver and spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/15\">",
"     15",
"    </a>",
"    ]. The additional increase is attributed to an inflammatory and hyperplastic cellular response. Although the pathogenetic mechanisms are not understood, Gaucher cells and neighboring macrophages overexpress and secrete lysosomal proteases, such as cathepsins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/16\">",
"     16",
"    </a>",
"    ], and inflammatory mediators such as interleukins 6, 8, 10 and macrophage inflammatory proteins (MIP) 1&alpha; and 1&beta; [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The Gaucher cells exhibit the secretory phenotype of the so-called &ldquo;alternatively activated&rdquo; macrophage. This phenotype is often associated in other conditions with chronic inflammation, healing, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/20\">",
"     20",
"    </a>",
"    ]. A mouse model of GD suggests that other cell types are affected, including thymic T cells, dendritic cells, and osteoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several pathologic processes occur within bone: decreased mineral density, marrow infiltration, and infarction of bone. The mechanisms leading to decreased bone mineral density are uncertain, but they may involve failure to achieve peak bone mass, abnormal osteoclast regulation, or overproduction of cytokines by activated macrophages. Marrow fibrosis and osteosclerosis result in localized loss of hematopoiesis. In an in vitro model of GD, primitive hematopoiesis and proliferation of mesenchymal progenitors were impaired, suggesting that cytopenias are due an intrinsic defect in addition to hypersplenism and bone marrow infiltration with Gaucher cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/22\">",
"     22",
"    </a>",
"    ]. Thrombocytopenia results from splenic sequestration and occasionally marrow failure. The increased bleeding tendency in patients with type 1 GD is related to thrombocytopenia, coagulation abnormalities, and defective platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8072432\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GD is an autosomal recessive disorder that is due to mutations in the glucocerebrosidase (GBA) gene located on chromosome 1q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/24\">",
"     24",
"    </a>",
"    ]. The gene is 7.6 kb in length and is composed of 11 exons. A 5 kb unprocessed pseudogene is located 16 kb downstream and is transcriptionally active [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/25\">",
"     25",
"    </a>",
"    ]. Care must be taken in molecular diagnosis and research to avoid analysis of the pseudogene and its transcripts in place of the active GBA gene.",
"   </p>",
"   <p>",
"    More than 200 distinct GBA gene mutations are listed in the Human Gene Mutation Database (",
"    <a class=\"external\" href=\"file://www.hgmd.cf.ac.uk/\">",
"     www.hgmd.cf.ac.uk",
"    </a>",
"    ). More than 80 percent of these mutations are single nucleotide substitutions. Insertions, deletions, and other complex alleles account for approximately 20 percent of mutations.",
"   </p>",
"   <p>",
"    Three mutant alleles are particularly frequent in affected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The c.1226A&gt;G mutation (N370S allele), which accounts for 53 percent of mutant alleles in the International Collaborative Gaucher Group (ICGG) Registry [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ], is a missense mutation that results in residual enzyme activity. There is a genotype-phenotype correlation in that the presence of the c.1226A&gt;G mutation in either homozygous or heterozygous form leads to type 1 GD, rather than a neurologic phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/6\">",
"       6",
"      </a>",
"      ]. The c.1226A&gt;G mutation is encountered commonly in non-Jewish Europeans and Ashkenazi Jews (gene frequency 0.032) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The c.1448T&gt;C mutation (L444P allele), which accounts for 18 percent of mutant alleles in the Gaucher registry [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ], is common in northern Sweden and elsewhere in Northern Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/28\">",
"       28",
"      </a>",
"      ]. It is generally associated with neuronopathic disease when present in homozygous form.",
"     </li>",
"     <li>",
"      The c.84dupG mutation (84GG allele), which represents approximately 7 percent of mutant alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ], results from an insertion at position 84 that causes a frameshift. It is a null mutation (ie, no protein is synthesized). Affected patients are compound heterozygotes; to date, homozygotes have not been described, presumably because of prenatal lethality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The c.1226A&gt;G, c.84dupG, and c.1448T&gt;C mutations account for approximately 94 percent of alleles in Ashkenazi patients (70, 12, and 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/27\">",
"     27",
"    </a>",
"    ]. The c.1226A&gt;G and c.1448T&gt;C mutations together account for approximately 70 percent of mutant alleles in non-Ashkenazi European patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Among patients being treated for GD, approximately 25 percent are c.1226A&gt;G homozygotes, whereas c.1226A&gt;G is paired with c.1448T&gt;C, c.84dupG, or a less common mutation in 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2\">",
"     2",
"    </a>",
"    ]. Mutant allele frequencies are different in Asian populations. As an example, the c.1226A&gt;G mutation was not found in a series of 36 Korean patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) involves the visceral organs, bone marrow, and bone in all affected patients. Disease severity can range from perinatal-lethal to asymptomatic. The presenting features are variable and may occur at any age. GD is categorized into three clinical types that are distinguished by their clinical features, course, and ethnic predilection (",
"    <a class=\"graphic graphic_table graphicRef56005 \" href=\"UTD.htm?40/14/41196\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/32\">",
"     32",
"    </a>",
"    ]. However, there is a broad spectrum of findings and overlap within and between types and intermediate phenotypes are appreciated, suggesting that GD is a spectrum of disease manifestations, rather than a disorder with three distinct subtypes.",
"   </p>",
"   <p>",
"    Type 1 GD (GD1, MIM #230800) is the most prevalent and occurs with greater frequency in the Ashkenazi Jewish population, although most patients with Type 1 GD are not Jewish. Types 2 and 3 are less common and occur in all ethnic types. Type 1 is distinguished from type 2 (GD2, MIM #230900) and type 3 (GD3, MIM #231000) by the lack of characteristic involvement of the central nervous system, although studies have documented several neurologic features in type 1 patients that are distinct from those observed in types 2 and 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/33\">",
"     33",
"    </a>",
"    ]. GD with neurologic involvement (neuronopathic GD) is designated as type 2 or 3 based on the acute or chronic nature, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H792532\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;GD has a variety of presenting features that may occur at any age with varying severity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26,29,31,34-36\">",
"     26,29,31,34-36",
"    </a>",
"    ]. The common presenting features seen in all types of GD are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef85527 \" href=\"UTD.htm?12/23/12668\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Type 2 disease constitutes 1 percent of patients in the Registry and type 3 constitutes 7 percent. Features seen only in type 2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type 3 GD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Developmental delay (type 2)",
"     </li>",
"     <li>",
"      Subtle cognitive problems on presentation that may later progress to developmental delay (type 3)",
"     </li>",
"     <li>",
"      Nonimmune hydrops (type 2)",
"     </li>",
"     <li>",
"      Congenital ichthyosis (type 2)",
"     </li>",
"     <li>",
"      Strabismus or supranuclear gaze palsy (types 2 and 3)",
"     </li>",
"     <li>",
"      Progressive dementia, ataxia and myoclonus (type 3, rare)",
"     </li>",
"     <li>",
"      Corneal opacity (type 3C, rare)",
"     </li>",
"     <li>",
"      Cardiovascular calcification (type 3C, rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients (usually type 1) may also present following splenectomy carried out either in the course of investigation of suspected malignancy or following traumatic splenic rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Type 1 (GD1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;GD1 is characterized by variability in signs, symptoms, severity, and progression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/34,37\">",
"     34,37",
"    </a>",
"    ], even among siblings with the same genotype and monozygotic twins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Symptomatic patients have visceral involvement, bone disease, and bleeding (",
"    <a class=\"graphic graphic_table graphicRef56005 \" href=\"UTD.htm?40/14/41196\">",
"     table 1",
"    </a>",
"    ). Fatigue is common and pubertal delay, with associated delay in growth, may occur. Bone disease is common in patients splenectomized for control of hematologic disease. Even &ldquo;asymptomatic&rdquo; individuals homozygous for the c.1226A&gt;G mutation appear to have GD manifestations, including anemia, thrombocytopenia, hepatosplenomegaly, marrow infiltration, bony abnormalities, and",
"    <span class=\"nowrap\">",
"     osteopenia/osteoporosis",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age of onset for GD1 is also variable. Some patients present between 12 and 24 months of age, whereas others have no clinical signs until late adulthood. Some individuals with this genotype remain asymptomatic throughout life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Visceral disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly is the most common presenting sign [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. The spleen can be enlarged as much as 5 to 75 times its normal size (median 15.2 times [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"     26",
"    </a>",
"    ]). Hepatomegaly is universal, but the liver increases relatively less than the spleen. Liver volume usually is increased two to three times normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"     26",
"    </a>",
"    ]. Hepatic fibrosis typically occurs, but hepatic failure, cirrhosis, or portal hypertension are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/42\">",
"     42",
"    </a>",
"    ], except in splenectomized patients.",
"   </p>",
"   <p>",
"    Hepatosplenomegaly may be asymptomatic or may be associated with early satiety, abdominal complaints (distension, discomfort, pain),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/34\">",
"     34",
"    </a>",
"    ]. Thrombocytopenia may result in bleeding and easy bruising. Splenic infarction occurs rarely and can present as acute abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bone marrow disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of anemia and thrombocytopenia in patients with GD is related to whether or not they have had a therapeutic splenectomy. Anemia, thrombocytopenia, or leukopenia may be present simultaneously or independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Skeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal manifestations are associated with a high degree of morbidity and impact on activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/1,43\">",
"     1,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skeletal disease is characterized by diffuse bone pain, punctuated by painful crises that often result in osteonecrosis (avascular necrosis) with subsequent joint collapse affecting the proximal and distal femur, proximal tibia, and proximal humerus. Osteolytic lesions, pathologic fractures, vertebral compression fractures, and other fragility fractures associated with low bone mineral density also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/34,44\">",
"     34,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from 1698 patients in the Gaucher Registry, 94 percent of whom had GD1, indicate that 63 percent had bone pain, 33 percent had bone crises, 8 percent had undergone joint replacement, and 94 percent had radiologic evidence of skeletal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"     26",
"    </a>",
"    ]. Bone pain, bone crises, and severe radiologic bone disease were more common among asplenic patients. Bone crises were more common among patients diagnosed before age 10 years than after age 10 years (42 versus 24 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Growth/development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many affected children grow poorly and have delayed puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/35,45-48\">",
"     35,45-48",
"    </a>",
"    ]. Approximately 50 percent of children with GD have height &le;5th percentile for age and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/45,47\">",
"     45,47",
"    </a>",
"    ], and 25 percent are shorter than expected based upon mid-parental height [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26,49\">",
"     26,49",
"    </a>",
"    ]. However, in one series, all patients had spontaneous catch-up, and 83 percent achieved a final height within the range of what was expected based upon mid-parental height [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/45\">",
"     45",
"    </a>",
"    ]. Most children with severe growth deficiency also have severe visceral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, other causes of growth retardation should be evaluated in otherwise mildly affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, puberty was delayed in 60 percent of 57 patients with GD in whom primary endocrine pathology was excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/45\">",
"     45",
"    </a>",
"    ]. Enzyme replacement therapy started before puberty improved growth and appeared to normalize the onset of puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link&amp;anchor=H4#H4\">",
"     \"Gaucher disease: Treatment\", section on 'Enzyme replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease is a less common manifestation of GD. It occurs when Gaucher cells infiltrate the alveolar spaces and interstitium. The abnormal cells can also occlude pulmonary capillaries, perhaps contributing to pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/51\">",
"     51",
"    </a>",
"    ], but a role for soluble mediators in remodeling of pulmonary vasculature is also proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/52\">",
"     52",
"    </a>",
"    ]. Hepatopulmonary syndrome, with characteristic hypoxemia on standing that results from abnormal vascular shunting with the lung, is a rare complication of Gaucher disease that usually occurs in splenectomized patients with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/42,53\">",
"     42,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=see_link\">",
"     \"Approach to the infant and child with interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic manifestations, such as peripheral polyneuropathy, are reported in GD1 even though it is &ldquo;nonneuronopathic&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/33,54,55\">",
"     33,54,55",
"    </a>",
"    ]. GD is also associated with Parkinson disease. GBA mutations in both homozygous and heterozygous forms are associated with a variety of Parkinson phenotypes that are earlier in onset and less dopamine-responsive than non-Gaucher associated Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/56\">",
"     56",
"    </a>",
"    ]. The mechanism underlying this association is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In addition, there is an increased frequency of heterozygosity for GBA mutations in cohorts of patients with sporadic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. Indeed, GBA mutations are the most frequent genetic associations with Parkinson disease in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/63\">",
"     63",
"    </a>",
"    ]. However, most patients with GD never develop Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"     26",
"    </a>",
"    ]. This suggests that GBA mutations may only increase the risk in individuals who are otherwise prone to developing Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/57,64\">",
"     57,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link\">",
"     \"Etiology and pathogenesis of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased rates of malignancies, particularly hematologic (lymphoma, leukemia, multiple myeloma), have been reported in patients with GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/65\">",
"     65",
"    </a>",
"    ]. Some patients have had multiple malignancies. Mutations in modifier genes may underlie the increased susceptibility to cancer in these patients. A homozygous mutation in the MSH6 gene that results in defective mismatch repair, for example, was identified in two siblings with GD1 and T cell acute lymphoblastic lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/66\">",
"     66",
"    </a>",
"    ]. Malignancy in Gaucher disease is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link&amp;anchor=H15486492#H15486492\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Type 2 (GD2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;GD2 is characterized by early onset, typically in the first year after birth (",
"    <a class=\"graphic graphic_table graphicRef56005 \" href=\"UTD.htm?40/14/41196\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/67\">",
"     67",
"    </a>",
"    ]. Visceral involvement is extensive and severe. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Visceral disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The first sign of central nervous system (CNS) disease typically is oculomotor dysfunction, which may include strabismus, saccade (fast eye movement) initiation abnormalities, and bulbar palsy or paresis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/4,68-70\">",
"     4,68-70",
"    </a>",
"    ]. Children with saccadic initiation abnormalities may compensate for lack of saccades by moving their head to shift their gaze [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/69\">",
"     69",
"    </a>",
"    ]. Neurologic progression is marked by severe hypertonia, rigidity, arching (opisthotonus), swallowing impairment, and seizures.",
"   </p>",
"   <p>",
"    Neuropathologic examination of patients with GD2 reveals extensive CNS abnormalities, including neuronal loss, gliosis, periadventitial Gaucher cells, neuronophagia, and free Gaucher cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/71\">",
"     71",
"    </a>",
"    ]. Involvement is widespread and includes the frontal cortex, thalamus, caudate, globus pallidus, pons, and cerebellum. The finding of neuronal loss suggests that the accumulated glycolipid, glucosylsphingosine in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/14\">",
"     14",
"    </a>",
"    ], is neurotoxic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Type 3 (GD3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 Gaucher disease (GD3) is the subacute or chronic neuronopathic form of GD (",
"    <a class=\"graphic graphic_table graphicRef56005 \" href=\"UTD.htm?40/14/41196\">",
"     table 1",
"    </a>",
"    ). It has a later onset than GD2. However, individuals with type 3 may have onset before age two years with very slow progressive nature. The distinction between Type 2 and 3 is therefore often difficult. Three forms of GD3 are recognized, although there is marked overlap supporting that this is a spectrum of disease manifestation and some authors have recommended eliminating the subclassification of type 3.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 3a is characterized by progressive dementia, ataxia, and myoclonus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=see_link\">",
"       \"Symptomatic (secondary) myoclonus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type 3b has extensive visceral and bone involvement with CNS involvement limited to supranuclear gaze palsy (saccade initiation failure, with compensatory head thrusting), either alone or associated with a more slowly progressive neurodegenerative syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/69,73,74\">",
"       69,73,74",
"      </a>",
"      ]. The Norrbottnian variant from Northern Sweden, associated with homozygosity for the c.1448T&gt;C mutation, belongs to this subcategory (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link\">",
"       \"Supranuclear disorders of gaze in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Type 3c (cardiovascular form) is rare and characterized by supranuclear gaze palsy, corneal opacity, and cardiovascular calcification, with little visceral disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/75-77\">",
"       75-77",
"      </a>",
"      ]. It is a unique phenotype associated with homozygosity for the D409H mutation (c.1342G&gt;C allele), usually found in populations originating from the Mediterranean basin [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/75,78,79\">",
"       75,78,79",
"      </a>",
"      ]. Neurologic involvement can begin late, and progression is variable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link\">",
"       \"Supranuclear disorders of gaze in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Audiometric testing may be helpful to evaluate brainstem disease in type 3 disease. In one study, children with this condition had abnormalities that included bilaterally increased acoustic reflexes, poor medial olivocochlear suppression, and very poor brainstem evoked potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10098520\">",
"    <span class=\"h2\">",
"     Other subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal-lethal form can present as nonimmune hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. This condition can be lethal in utero or in the newborn period. GD should be considered in the differential diagnosis of pregnancy loss accompanied by severe hydrops. They may present clinically with congenital ichthyosis, also known as collodion baby [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/71,83\">",
"     71,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H2#H2\">",
"     \"The genodermatoses\", section on 'Disorders of keratinization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8074611\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophages filled with lipid material are known as Gaucher cells and are a cardinal feature of the disease. Gaucher cells have a characteristic histologic appearance of wrinkled tissue paper. Membrane-bound inclusions filled with glucocerebroside are seen with electron microscopy. Gaucher cells have the protein expression profile of the so-called alternatively activated macrophage, a phenotype associated with chronic inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombocytopenia and anemia typically are found on blood count. Liver enzymes may be mildly elevated, and serum angiotensin converting enzyme (ACE) may be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/85\">",
"     85",
"    </a>",
"    ]. Acid phosphatase activity, particularly the tartrate-resistant isoenzyme, is elevated. Hyperferritinemia is common and is associated with increased liver volume and prior splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory evaluation of GD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link&amp;anchor=H8#H8\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20909219\">",
"    <span class=\"h1\">",
"     RADIOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies can suggest the diagnosis of GD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its complications [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/87\">",
"     87",
"    </a>",
"    ]. Radiologic findings were found with the following frequencies in the Gaucher Registry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The characteristic Erlenmeyer flask deformity of the distal femur caused by abnormal modeling of the metaphysis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64962 \" href=\"UTD.htm?33/36/34382\">",
"       image 1",
"      </a>",
"      ) was present in 46 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ]. Although this finding is not specific for GD, it has a limited differential diagnosis (fibrous dysplasia, Niemann-Pick disease, osteopetrosis, heavy metal poisoning).",
"     </li>",
"     <li>",
"      Fractures and lytic lesions were present on plain radiographs in 15 and 8 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ]. Irreversible skeletal lesions were present in 17 percent of c.1226A&gt;G homozygotes and 26 percent of c.1226A&gt;G compound heterozygotes among type 1 GD patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marrow infiltration was present on magnetic resonance imaging (MRI) in 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bone infarction and osteonecrosis were each present on MRI in 25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteopenia was present on dual energy X-ray absorptiometry (DEXA) in 42 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The radiologic evaluation of GD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link&amp;anchor=H9#H9\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\", section on 'Radiology evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GD is confirmed by the finding of reduced glucocerebrosidase activity, usually in peripheral leukocytes, in a patient with clinical features consistent with GD. Mutation analysis provides additional confirmation of the diagnosis and can help predict clinical manifestations and identify undiagnosed affected family members and heterozygote carriers (under certain circumstances) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation is directed toward assessment of disease severity and detection of concomitant conditions that can be aggravated by GD once the diagnosis is confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=see_link\">",
"     \"Gaucher disease: Initial assessment, monitoring, and clinical course\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Enzyme analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GD is usually confirmed by the finding of reduced glucocerebrosidase activity in peripheral leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/88\">",
"     88",
"    </a>",
"    ]. The enzyme activity varies in each white cell type, decreasing from monocytes to lymphocytes to granulocytes. The diagnosis can also be made by measuring glucocerebrosidase activity in cultured skin fibroblasts or other nucleated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/34,89-92\">",
"     34,89-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peripheral leukocyte assay uses an artificial substrate, 4-methylumbilliferyl-beta-glucoside. With this assay, type 1 patients generally demonstrate residual enzymatic activity (10 to 15 percent of the control enzyme activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/88\">",
"     88",
"    </a>",
"    ]. Type 2 and 3 patients generally have much lower activity, but cannot reliably be distinguished from each other. Activity in heterozygote carriers and normal individuals shows considerable overlap. Thus, enzyme analysis cannot be used alone to distinguish carriers from noncarriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mutation analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted DNA analysis to detect the most common mutations is an effective method for confirming the diagnosis and is the first-line option for carrier identification among family members. However, the failure to find a mutation in a limited panel does not exclude the diagnosis, because of the heterogeneity of affected alleles. Uncommon alleles occur more often in the non-Ashkenazi than in Ashkenazi ethnic groups. DNA sequencing of the entire GBA coding region is clinically available as a second-tier test when targeted mutation analysis fails to identify both mutant alleles in a patient with deficient glucocerebrosidase activity.",
"   </p>",
"   <p>",
"    Mutation analysis may help to classify patients and predict clinical findings. As an example, 65 to 75 percent of individuals who are homozygous for the c.1226A.G mutation have symptoms of GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/93\">",
"     93",
"    </a>",
"    ], but do not have neurologic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/94\">",
"     94",
"    </a>",
"    ]. The D409H allele is uniquely associated with cardiovascular and corneal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutation analysis can definitively identify carriers of specific mutations segregating within a family, but cannot exclude carrier status among unrelated individuals, except through complete sequencing of the GBA gene.",
"   </p>",
"   <p>",
"    The 55-bp deletion in exon 9 overlaps with the c.1226A&gt;G mutation. Therefore, all individuals homozygous for the c.1226A&gt;G mutation should be further evaluated with parental samples or by a specific test designed to detect the 55-bp deletion. Recombinant (Rec) alleles contain two to four point mutations, including c.1448T&gt;C, resulting from gene rearrangement between exon 9 and 10 of the functional gene and pseudogene, respectively. Thus, the testing for c.1448T&gt;C mutation alone does not allow detection of the Rec allele. This requires a specifically designed test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is often made when Gaucher cells are detected in the bone marrow of patients who are being evaluated for splenomegaly, anemia, or thrombocytopenia (",
"    <a class=\"graphic graphic_picture graphicRef59255 \" href=\"UTD.htm?14/18/14630\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/95\">",
"     95",
"    </a>",
"    ]. However, bone marrow studies are not necessary to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is performed by enzyme analysis of fetal cells obtained by chorionic villus sampling or amniocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/96\">",
"     96",
"    </a>",
"    ]. Obtaining a skin biopsy from the proband and assaying cultured skin fibroblasts simultaneously with the prenatal sample is helpful in cases where there may be significant residual enzymatic activity. Knowledge of the DNA mutations in the proband or in the heterozygous parents allows the use of DNA mutation analysis together with enzyme analysis for prenatal diagnosis. Mutation analysis is recommended as a confirmatory assay. Preimplantation genetic diagnosis is also possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20908218\">",
"     'Genetic counseling'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to prenatal screening in Ashkenazi Jews are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link&amp;anchor=H31#H31\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\", section on 'Gaucher disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20908218\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence risk for a couple who has a child with GD is 1:4 if both parents are heterozygotes and 1:2 if one of the parents is affected and the other is a heterozygous carrier.",
"   </p>",
"   <p>",
"    Prediction of disease severity based on genotype is only approximate, because of the wide range of phenotypic variability. There is a recognized association of disease severity with genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2\">",
"     2",
"    </a>",
"    ], although this is not always the case [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, the use of genotype-phenotype correlations in counseling should be approached with care.",
"   </p>",
"   <p>",
"    When the parents are heterozygous carriers of one of the common alleles, parental genotype can provide some guidance for prenatal counseling, as indicated below [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If both parents are heterozygotes for c.1226A&gt;G, affected children will have type 1 GD and will not have neurologic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/98\">",
"       98",
"      </a>",
"      ]. It is probable that the child will have a milder disease course or possibly be asymptomatic well into adulthood, but severe disease with early onset has been observed.",
"     </li>",
"     <li>",
"      If the fetus is at risk for the",
"      <span class=\"nowrap\">",
"       c.1226A&gt;G/c.84dupG",
"      </span>",
"      or c.1226A&gt;G",
"      <span class=\"nowrap\">",
"       /c.1448T&gt;C",
"      </span>",
"      genotype, neurologic disease is not expected, but the disease course is expected to be more severe than observed in c.1226A&gt;G homozygotes. The median age of onset of symptoms for children with these compound heterozygote genotypes is six years [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the fetus is at risk for the c.1448T&gt;C homozygous genotype, severe visceral and skeletal disease is probable, and there is a high likelihood of neurologic disease, generally occurring early in the course [",
"      <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/100-102\">",
"       100-102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H792367\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of GD depends upon the presenting symptoms and signs. Splenomegaly, anemia, and thrombocytopenia can result from many disorders. Conditions including leukemia, lymphoma, inflammatory diseases such as rheumatoid arthritis, or other storage diseases, such as Niemann-Pick types A, B, or C [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/103\">",
"     103",
"    </a>",
"    ], often are considered in the differential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=see_link\">",
"     \"Approach to the child with an enlarged spleen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=see_link\">",
"     \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Osteopenia, pathologic fractures, and bone pain are features of metabolic bone disease from a variety of causes, including rickets, vitamin C deficiency, copper deficiency, sickle cell disease, Paget disease, and a number of inherited disorders associated with renal disease or skeletal abnormalities. Most of these disorders have characteristic clinical, radiographic, or laboratory features that distinguish them from GD.",
"   </p>",
"   <p>",
"    Deficiency of saposin C (MIM #610539, also called atypical GD) results in a severe disorder similar to GD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/11/9402/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gaucher disease (GD) is the most common lysosomal storage disease. It is caused by deficiency of glucocerebrosidase (GBA), which results in abnormal accumulation of glycolipids within cellular lysosomes. GD is one of the few inherited metabolic disorders that can be treated by enzyme replacement therapy. Because early treatment can prevent development of irreversible complications, early identification is crucial to improving ultimate outcome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GD is an autosomal recessive disorder caused by mutations in the glucocerebrosidase (GBA) gene located on chromosome 1q21. More than 200 distinct mutations are reported. However three mutant alleles account for most cases: c.1226A&gt;G (N370S), c.1448T&gt;C (L444P), and c.84dupG (84GG). The prevalence of these alleles varies with ethnicity. The c.1226A&gt;G mutation is encountered commonly in non-Jewish Europeans and Ashkenazi Jews, whereas c.1448T&gt;C is relatively common in Sweden and Northern Europe. Disease onset, severity, and clinical manifestations vary with the genotype, although the genotype-phenotype correlation is not entirely consistent. (See",
"      <a class=\"local\" href=\"#H8072432\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20908218\">",
"       'Genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presenting features of GD are variable and may occur at any age. GD is classified into three clinical types (",
"      <a class=\"graphic graphic_table graphicRef56005 \" href=\"UTD.htm?40/14/41196\">",
"       table 1",
"      </a>",
"      ). The visceral organs, bone marrow, and bone are affected in all types. Type 1 is distinguished from types 2 and 3 by the lack of characteristic involvement of the central nervous system. GD with neurologic involvement (neuronopathic GD) is designated as type 2 or 3 based on the acute or chronic nature, respectively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of GD is confirmed by the finding of reduced glucocerebrosidase activity in peripheral leukocytes. Diagnosis can also be confirmed by mutation analysis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/1\">",
"      Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"     </a>",
"    </li>",
"    <li>",
"     Beutler E, Grabowski GA. Gaucher disease. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.3635.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/3\">",
"      Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/4\">",
"      Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005; 17:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/5\">",
"      Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997; 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/6\">",
"      Koprivica V, Stone DL, Park JK, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000; 66:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Locatelli Hoops S, Kolter T, Sandhoff K. Saposin C and other sphingolipid activator proteins. In: Gaucher disease, Futerman AH, Zimran A (Eds), CRC Press, Boca Raton 2006. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/8\">",
"      Dionisi-Vici C, Rizzo C, Burlina AB, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002; 140:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/9\">",
"      Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/10\">",
"      Sidransky E. New perspectives in type 2 Gaucher disease. Adv Pediatr 1997; 44:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/11\">",
"      Tylki-Szyma��ska A, Vellodi A, El-Beshlawy A, et al. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 2010; 33:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/12\">",
"      Messner MC, Cabot MC. Glucosylceramide in humans. Adv Exp Med Biol 2010; 688:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/13\">",
"      Svennerholm L, H&aring;kansson G, M&aring;nsson JE, Nilsson O. Chemical differentiation of the Gaucher subtypes. Prog Clin Biol Res 1982; 95:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/14\">",
"      Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 2002; 76:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/15\">",
"      Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 2001; 24 Suppl 2:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/16\">",
"      Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000; 96:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/17\">",
"      Allen MJ, Myer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 1997; 90:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/18\">",
"      Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/19\">",
"      Pavlova EV, Deegan PB, Tindall J, et al. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis 2011; 46:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/20\">",
"      Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007; 117:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/21\">",
"      Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 2010; 107:19473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/22\">",
"      Berger J, Lecourt S, Vanneaux V, et al. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 2010; 150:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/23\">",
"      Spectre G, Roth B, Ronen G, et al. Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleeding. Br J Haematol 2011; 153:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/24\">",
"      Cormand B, Montfort M, Chab&aacute;s A, et al. Genetic fine localization of the beta-glucocerebrosidase (GBA) and prosaposin (PSAP) genes: implications for Gaucher disease. Hum Genet 1997; 100:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/25\">",
"      Horowitz M, Wilder S, Horowitz Z, et al. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/26\">",
"      Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/27\">",
"      Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993; 52:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/28\">",
"      Dahl N, Lagerstr&ouml;m M, Erikson A, Pettersson U. Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am J Hum Genet 1990; 47:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/29\">",
"      Amaral O, Lacerda L, Santos R, et al. Type 1 Gaucher disease: molecular, biochemical, and clinical characterization of patients from northern Portugal. Biochem Med Metab Biol 1993; 49:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/30\">",
"      Alfonso P, Cenarro A, P&eacute;rez-Calvo JI, et al. Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations. Blood Cells Mol Dis 2001; 27:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/31\">",
"      Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011; 46:11.",
"     </a>",
"    </li>",
"    <li>",
"     Online Mendelian Inheritance in Man www.ncbi.nlm.nih.gov/Omim.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/33\">",
"      Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008; 31:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/34\">",
"      Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/35\">",
"      Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006; 160:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/36\">",
"      Rossi L, Zulian F, Stirnemann J, et al. Bone involvement as presenting sign of pediatric-onset Gaucher disease. Joint Bone Spine 2011; 78:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/37\">",
"      Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis 2008; 31:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/38\">",
"      Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 2004; 97:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/39\">",
"      Elstein D, Gellman A, Altarescu G, et al. Disease severity in sibling pairs with type 1 Gaucher disease. J Inherit Metab Dis 2010; 33:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/40\">",
"      Balwani M, Fuerstman L, Kornreich R, et al. Type 1 Gaucher disease: significant disease manifestations in \"asymptomatic\" homozygotes. Arch Intern Med 2010; 170:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/41\">",
"      Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 2011; 86:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/42\">",
"      Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000; 93:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/43\">",
"      Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 2011; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/44\">",
"      Rodrigue SW, Rosenthal DI, Barton NW, et al. Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop Relat Res 1999; :201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/45\">",
"      Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000; 2:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/46\">",
"      Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002; 75 Suppl 1:A37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/47\">",
"      Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996; 129:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/48\">",
"      Zevin S, Abrahamov A, Hadas-Halpern I, et al. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med 1993; 86:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/49\">",
"      Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/50\">",
"      Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996; 11:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/51\">",
"      Ross DJ, Spira S, Buchbinder NA. Gaucher cells in pulmonary-capillary blood in association with pulmonary hypertension. N Engl J Med 1997; 336:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/52\">",
"      Elstein D, Nir A, Klutstein M, et al. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. Blood Cells Mol Dis 2005; 34:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/53\">",
"      Kim JH, Park CH, Pai MS, et al. Hepatopulmonary syndrome in Gaucher disease with right-to-left shunt: evaluation and measurement using Tc-99m MAA. Clin Nucl Med 1999; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/54\">",
"      Biegstraaten M, Mengel E, Mar&oacute;di L, et al. Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010; 133:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/55\">",
"      Ch&eacute;rin P, Rose C, de Roux-Serratrice C, et al. The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J Inherit Metab Dis 2010; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/56\">",
"      Goker-Alpan O, Lopez G, Vithayathil J, et al. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/57\">",
"      Sidransky E. Gaucher disease and parkinsonism. Mol Genet Metab 2005; 84:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/58\">",
"      Goldin E. Gaucher disease and parkinsonism, a molecular link theory. Mol Genet Metab 2010; 101:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/59\">",
"      Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/60\">",
"      Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004; 81:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/61\">",
"      Clark LN, Nicolai A, Afridi S, et al. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord 2005; 20:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/62\">",
"      Sato C, Morgan A, Lang AE, et al. Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord 2005; 20:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/63\">",
"      Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/64\">",
"      Sidransky E. Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 2006; 70:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/65\">",
"      Lo SM, Stein P, Mullaly S, et al. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol 2010; 85:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/66\">",
"      Lo SM, Choi M, Liu J, et al. Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. Blood 2012; 119:4731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/67\">",
"      Gupta N, Oppenheim IM, Kauvar EF, et al. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis 2011; 46:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/68\">",
"      Cohen IJ, Katz K, Kornreich L, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 1998; 24:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/69\">",
"      Harris CM, Taylor DS, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics 1999; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/70\">",
"      Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/71\">",
"      Finn LS, Zhang M, Chen SH, Scott CR. Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses. Am J Med Genet 2000; 91:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/72\">",
"      Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997; 10:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/73\">",
"      Blom S, Erikson A. Gaucher disease--Norrbottnian type. Neurodevelopmental, neurological, and neurophysiological aspects. Eur J Pediatr 1983; 140:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/74\">",
"      Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993; 43:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/75\">",
"      Abrahamov A, Elstein D, Gross-Tsur V, et al. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 1995; 346:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/76\">",
"      Bohlega S, Kambouris M, Shahid M, et al. Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC). Neurology 2000; 54:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/77\">",
"      Chab&aacute;s A, Cormand B, Balcells S, et al. Neuronopathic and non-neuronopathic presentation of Gaucher disease in patients with the third most common mutation (D409H) in Spain. J Inherit Metab Dis 1996; 19:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/78\">",
"      Chab&aacute;s A, Gort L, Montfort M, et al. Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis. J Med Genet 1998; 35:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/79\">",
"      Michelakakis H, Skardoutsou A, Mathioudakis J, et al. Early-onset severe neurological involvement and D409H homozygosity in Gaucher disease: outcome of enzyme replacement therapy. Blood Cells Mol Dis 2002; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/80\">",
"      Bamiou DE, Campbell P, Liasis A, et al. Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics 2001; 32:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/81\">",
"      Tayebi N, Cushner SR, Kleijer W, et al. Prenatal lethality of a homozygous null mutation in the human glucocerebrosidase gene. Am J Med Genet 1997; 73:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/82\">",
"      Mignot C, Gelot A, Bessi&egrave;res B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A 2003; 120A:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/83\">",
"      Stone DL, Carey WF, Christodoulou J, et al. Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed 2000; 82:F163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/84\">",
"      Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004; 122:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/85\">",
"      Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gaucher's disease. N Engl J Med 1976; 294:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/86\">",
"      Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 2010; 85:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/87\">",
"      Katz R, Booth T, Hargunani R, et al. Radiological aspects of Gaucher disease. Skeletal Radiol 2011; 40:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/88\">",
"      Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin Genet 1978; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/89\">",
"      Hultberg B, Sj&ouml;blad S, Ockerman PA. 4-Methylumbelliferyl-beta-glucosidase in cultured human fibroblasts from controls and patients with Gaucher's disease. Clin Chim Acta 1973; 49:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/90\">",
"      Ho MW, Seck J, Schmidt D, et al. Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid beta-glucosidase in cultured fibroblasts. Am J Hum Genet 1972; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/91\">",
"      Turner BM, Hirschhorn K. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease. Am J Hum Genet 1978; 30:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/92\">",
"      Choy FY, Davidson RG. Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues. Pediatr Res 1980; 14:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/93\">",
"      Strasberg PM, Triggs-Raine BL, Warren IB, et al. Genotype-phenotype pitfalls in Gaucher disease. J Clin Lab Anal 1994; 8:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/94\">",
"      Sidransky E, Bottler A, Stubblefield B, Ginns EI. DNA mutational analysis of type 1 and type 3 Gaucher patients: how well do mutations predict phenotype? Hum Mutat 1994; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/95\">",
"      Beutler E, Saven A. Misuse of marrow examination in the diagnosis of Gaucher disease. Blood 1990; 76:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/96\">",
"      Svennerholm L, H&aring;kansson G, Lindsten J, et al. Prenatal diagnosis of Gaucher disease. Assay of the beta-glucosidase activity in amniotic fluid cells cultivated in two laboratories with different cultivation conditions. Clin Genet 1981; 19:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/97\">",
"      Altarescu G, Renbaum P, Eldar-Geva T, et al. Preimplantation genetic diagnosis (PGD) for a treatable disorder: Gaucher disease type 1 as a model. Blood Cells Mol Dis 2011; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/98\">",
"      Theophilus B, Latham T, Grabowski GA, Smith FI. Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet 1989; 45:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/99\">",
"      Beutler E. Gaucher's disease. N Engl J Med 1991; 325:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/100\">",
"      Sidransky E. Gaucher disease: complexity in a \"simple\" disorder. Mol Genet Metab 2004; 83:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/101\">",
"      Tsuji S, Choudary PV, Martin BM, et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med 1987; 316:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/102\">",
"      Tylki-Szyma��ska A, Millat G, Maire I, Czartoryska B. Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 1996; 4:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/103\">",
"      Lo SM, McNamara J, Seashore MR, Mistry PK. Misdiagnosis of Niemann-Pick disease type C as Gaucher disease. J Inherit Metab Dis 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/104\">",
"      Schnabel D, Schr&ouml;der M, Sandhoff K. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett 1991; 284:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/11/9402/abstract/105\">",
"      Vaccaro AM, Motta M, Tatti M, et al. Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet 2010; 19:2987.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2918 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9402=[""].join("\n");
var outline_f9_11_9402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H792429\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8072432\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H792532\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Type 1 (GD1)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Visceral disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bone marrow disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Skeletal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Growth/development",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Type 2 (GD2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Type 3 (GD3)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10098520\">",
"      Other subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8074611\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20909219\">",
"      RADIOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Enzyme analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mutation analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20908218\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H792367\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2918|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/36/34382\" title=\"diagnostic image 1\">",
"      Erlenmeyer flask deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2918|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14630\" title=\"picture 1\">",
"      Gaucher cells in marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/14/41196\" title=\"table 1\">",
"      Gaucher disease classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/23/12668\" title=\"table 2\">",
"      Major clinical manifestations of GD at presentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=related_link\">",
"      Approach to the child with an enlarged spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26985?source=related_link\">",
"      Approach to the infant and child with interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=related_link\">",
"      Clinical manifestations and evaluation of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=related_link\">",
"      Etiology and pathogenesis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/40/12937?source=related_link\">",
"      Gaucher disease: Initial assessment, monitoring, and clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=related_link\">",
"      Gaucher disease: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/34/30249?source=related_link\">",
"      Symptomatic (secondary) myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_11_9403="Nail surgery history";
var content_f9_11_9403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relevant history aspects for patients undergoing nail surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Raynaud phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disease, including heart block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prosthetic heart valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prosthetic joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications known to interfere with anesthetic drugs or coagulation (eg, beta blockers, phenothiazines, anticoagulants, aspirin, NSAIDs)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9403=[""].join("\n");
var outline_f9_11_9403=null;
var title_f9_11_9404="Ovulation induction in PCOS";
var content_f9_11_9404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison between laparoscopic ovulation induction and gonadotropin ovulation induction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laparoscopy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonadotropin administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Advantages",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Pregnancy rates comparable to gonadotropins",
"        </p>",
"        <p>",
"         No additional procedures required",
"        </p>",
"        <p>",
"         Minimal monitoring required",
"        </p>",
"        <p>",
"         One treatment produces multiple ovulatory cycles",
"        </p>",
"        <p>",
"         Usually produces monovulatory cycles",
"        </p>",
"        <p>",
"         No increased risk of ovarian hyperstimulation",
"        </p>",
"        <p>",
"         No expensive medications required",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         High probability of successful ovulation induction",
"        </p>",
"        <p>",
"         Conception rates comparable to laparoscopy",
"        </p>",
"        <p>",
"         No known risk of adhesive damage",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Disadvantages",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Initial surgery not entirely risk-free",
"        </p>",
"        <p>",
"         Adhesions",
"        </p>",
"        <p>",
"         Ovarian atrophy",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         High cost",
"        </p>",
"        <p>",
"         Intensive monitoring required",
"        </p>",
"        <p>",
"         One ovulatory event per cycle",
"        </p>",
"        <p>",
"         Increased risk of multiple gestations",
"        </p>",
"        <p>",
"         Increased risk of ovarian hyperstimulation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9404=[""].join("\n");
var outline_f9_11_9404=null;
var title_f9_11_9405="Radiologic evaluation of the C spine";
var content_f9_11_9405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of indications for radiologic evaluation of the cervical spine in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Radiologic study",
"       </td>",
"       <td class=\"subtitle1\">",
"        History and physical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        None",
"       </td>",
"       <td>",
"        Low risk mechanism of injury,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No distracting pain or injuries,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Awake and able to verbalize and cooperate with exam,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No mental status changes,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No neck pain or limitation of movement,*",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No neurologic deficits",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"10\">",
"        Lateral, AP, odontoid films",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        High-risk mechanisms of injury,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple system trauma with severe injuries,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other pain or injuries that distract the patient,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injury above the clavicles,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered mental status after head trauma,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unable to verbalize or cooperate with the examination,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain on the top of the head,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck pain, tenderness, or deformity,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute neurologic deficit, especially paresthesias,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limitation of neck movement",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        CT",
"       </td>",
"       <td>",
"        Lower or upper C-spine not visualized on plain films, if indicated,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal or suspicious C-spine on plain films,",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspicion of injury despite normal plain cervical radiographs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Flexion-extension films",
"       </td>",
"       <td>",
"        Normal C-spine films,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No neurologic deficit referable to C-spine,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continued neck pain, tenderness, or muscle spasm,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Able to actively flex and extend neck for the examination",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        MRI",
"       </td>",
"       <td>",
"        Children with an abnormal neurologic examination and those requiring imaging of the soft tissues of the spinal column and spinal cord (eg, patients with normal plain films but persistent concern for neurologic injury based upon history, patients with prolonged loss of consciousness in whom cervical spine cannot be cleared by 24 to 72 hours post injury)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Able to move head in flexion and extension and rotate 45 degrees to both sides without pain.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Odontoid plain radiographs may be omitted in uncooperative children. However, children with possible upper cervical spine injury by history or physical examination, should undergo computed tomography of C1.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Source: Chung S, Mikrogianakis A, Wales PW, et al. Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. J Trauma 2011; 70:873.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9405=[""].join("\n");
var outline_f9_11_9405=null;
var title_f9_11_9406="Cardiac risk increases with the number of risk factors";
var content_f9_11_9406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Incidence of major cardiac complications increases with the number of risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 4513 patients, the incidence of a major cardiac complication increases with a higher cardiac risk index (1 to 4), which is based upon six independent predictors, including high-risk type of surgery, history of ischemic heart disease, history of heart failure, history of cerebrovascular disease, preoperative treatment with insulin, and preoperative serum creatinine &gt;2.0 mg/dL (177 mol/L). By definition, patients undergoing abdominal aortic aneurysm (AAA), thoracic, and abdominal procedures were excluded from class I. In all subsets, except patients undergoing AAA, there was a statistically significant trend toward greater risk with higher risk class.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lee TH, Marcantonio ER, Mangione CM, et al. Circulation 1999; 100:1043.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9406=[""].join("\n");
var outline_f9_11_9406=null;
var title_f9_11_9407="CBD obstruction dilated";
var content_f9_11_9407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anastomotic stricture following balloon dilation in a liver tranplatation recipient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cholangiogram obtained following balloon dilation of an anastomotic stricture in a patient who underwent liver transplantation demonstrates dilated intrahepatic ducts and a residual, but wider, stricture at the anastamosis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_11_9407=[""].join("\n");
var outline_f9_11_9407=null;
